CA1073913A - Amphetamine derivatives - Google Patents
Amphetamine derivativesInfo
- Publication number
- CA1073913A CA1073913A CA318,312A CA318312A CA1073913A CA 1073913 A CA1073913 A CA 1073913A CA 318312 A CA318312 A CA 318312A CA 1073913 A CA1073913 A CA 1073913A
- Authority
- CA
- Canada
- Prior art keywords
- group
- lower alkyl
- alkyl group
- methyl
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 53
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 21
- 125000005843 halogen group Chemical group 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 125000002252 acyl group Chemical group 0.000 claims abstract description 15
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical group N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 8
- 150000001299 aldehydes Chemical class 0.000 claims description 8
- 239000005695 Ammonium acetate Substances 0.000 claims description 7
- 229940043376 ammonium acetate Drugs 0.000 claims description 7
- 235000019257 ammonium acetate Nutrition 0.000 claims description 7
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 claims description 6
- 150000002825 nitriles Chemical class 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 125000004971 nitroalkyl group Chemical group 0.000 claims description 3
- -1 alkali metal cyanide Chemical class 0.000 claims description 2
- XZWMCPUAUNHGPF-UHFFFAOYSA-N 4-(dimethylamino)-2-methylbenzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C(C)=C1 XZWMCPUAUNHGPF-UHFFFAOYSA-N 0.000 claims 1
- JVMSKGOQBHOVAB-UHFFFAOYSA-N n,n,3-trimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC=C(C=C(C)[N+]([O-])=O)C(C)=C1 JVMSKGOQBHOVAB-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract description 3
- 239000000935 antidepressant agent Substances 0.000 abstract description 3
- 229940005513 antidepressants Drugs 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 41
- 235000013350 formula milk Nutrition 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000001828 Gelatine Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 229940083608 sodium hydroxide Drugs 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 5
- 229910000091 aluminium hydride Inorganic materials 0.000 description 5
- 229940025084 amphetamine Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- OYJXTOVLKZDGFK-UHFFFAOYSA-N ethanol;2-propan-2-yloxypropane Chemical compound CCO.CC(C)OC(C)C OYJXTOVLKZDGFK-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229940072690 valium Drugs 0.000 description 3
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 230000002743 euphoric effect Effects 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XSQFAWMDRFSIMY-UHFFFAOYSA-N 2-chloro-4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C(Cl)=C1 XSQFAWMDRFSIMY-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- PIAOLBVUVDXHHL-UHFFFAOYSA-N 2-nitroethenylbenzene Chemical class [O-][N+](=O)C=CC1=CC=CC=C1 PIAOLBVUVDXHHL-UHFFFAOYSA-N 0.000 description 1
- ONPPYVIEJPDKTI-UHFFFAOYSA-N 3,5-dichloro-n,n-dimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC(Cl)=C(C=C(C)[N+]([O-])=O)C(Cl)=C1 ONPPYVIEJPDKTI-UHFFFAOYSA-N 0.000 description 1
- YJCNUSPWDQIVAI-UHFFFAOYSA-N 3,5-dichloro-n,n-dimethylaniline Chemical compound CN(C)C1=CC(Cl)=CC(Cl)=C1 YJCNUSPWDQIVAI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000007164 Haack reaction Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001163743 Perlodes Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- RNIPBGMVTAUWNH-UHFFFAOYSA-N [F].[I] Chemical compound [F].[I] RNIPBGMVTAUWNH-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CWOMTHDOJCARBY-UHFFFAOYSA-N n,n,3-trimethylaniline Chemical compound CN(C)C1=CC=CC(C)=C1 CWOMTHDOJCARBY-UHFFFAOYSA-N 0.000 description 1
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 101150115956 slc25a26 gene Proteins 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ABSTRACT
This invention relates to compounds conforming to the general formula:
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; represents either (i) a group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, and when X is a group R represents a lower alkyl group, a benzyl group, a lower aliphatic acyl group or a benzoyl group or when X is a group R represents a lower alkyl or benzyl group; and R4 represents a hydrogen atom, a lower alkyl group a benzyl group or a -CH2CH2CH2 bridge converted to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or when R represents an acetyl group and R4 a hydrogen atom or (b) X is a
This invention relates to compounds conforming to the general formula:
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; represents either (i) a group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, and when X is a group R represents a lower alkyl group, a benzyl group, a lower aliphatic acyl group or a benzoyl group or when X is a group R represents a lower alkyl or benzyl group; and R4 represents a hydrogen atom, a lower alkyl group a benzyl group or a -CH2CH2CH2 bridge converted to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or when R represents an acetyl group and R4 a hydrogen atom or (b) X is a
Description
.3 :. .
. ~
, This application is a divisional of our copending Canadian Patent Application Serial No. 208,356 filed September 3, 1974.
~! This invention relates to new intermediates useful in the pre-paration of novel 4~aminoamphetamine derivatives having useful pharmacological properties particularly as antidepressants.
3 Depressive disorders have with more or less success been treated with various compounds. Many types of chemical substances have been usedJ
! among these amphetamine with the structure. `
1 :
;~ C 3 ,, CH2-CH-NH ~ :
.1 1 .:
`, 10 However, the euphoretic effect and the risk for dependence have l to a great extent restricted the use of amphetamine in the therapy. ` `
'~`1 .. . .
~ The medical use of amphetamine is nowadays mainly restricted to 1 .
the treatment of narcolepsy and asthenic states in aged people.
We have found that by proper substitution of amphetamine the euphoric or central stimulant effect of the substance can be diminished or -completely abolished. The pharmacological profile of the compounds of the ~ ` invention suggests a potential value of the compounds as antidepressants and '1 also as a new type of anxiolytics. ~,~
More particularly we have found that compounds of *he formula can be prepared by a process which comprises a) reducing a compound of the formula '~'1 .
- 1 - :
P~
i,'l, , .~,, ~, , , . , . . , , :: .. , . : .
. , .. : , . :
: ~ , , . . . ~ . :
'.! R6 '~
;CH = C - NO I I
!,. 1 2 '1l Rl ~ \ :
R2 ~t ~, ~
~. N ~ -.::: :
,. 3/ \ 4- :-wherein Rl, R2, R3, R4 and R6 have the above given definition, to the forma-tion o a compound of the formula:I, wherein R5 is a hydrogen atom; ~. . .
b) reducing a compound of the formula :
~. R6 '"' ICH C N2 .
'1 2 = ~
~'! R3' \ R4/ .. ~ .
,,,,~ ~; .
.; ~
wherein Rl, R2, R4 and R6 have the above given definition and R3 is a lower ~ .
il;; aliphatic acyl group or a benzoyl group, to the formation of a compound of ~ : the formula I wherein R5 is a hydrogen atom;
."~ c) halogenating a compound of the formula . ;
; ~1 R6 Rl~
.¦ N
R R
wherein R3, R4, R5 and R6 have the above given definition and e1ther R or R
. ~
, This application is a divisional of our copending Canadian Patent Application Serial No. 208,356 filed September 3, 1974.
~! This invention relates to new intermediates useful in the pre-paration of novel 4~aminoamphetamine derivatives having useful pharmacological properties particularly as antidepressants.
3 Depressive disorders have with more or less success been treated with various compounds. Many types of chemical substances have been usedJ
! among these amphetamine with the structure. `
1 :
;~ C 3 ,, CH2-CH-NH ~ :
.1 1 .:
`, 10 However, the euphoretic effect and the risk for dependence have l to a great extent restricted the use of amphetamine in the therapy. ` `
'~`1 .. . .
~ The medical use of amphetamine is nowadays mainly restricted to 1 .
the treatment of narcolepsy and asthenic states in aged people.
We have found that by proper substitution of amphetamine the euphoric or central stimulant effect of the substance can be diminished or -completely abolished. The pharmacological profile of the compounds of the ~ ` invention suggests a potential value of the compounds as antidepressants and '1 also as a new type of anxiolytics. ~,~
More particularly we have found that compounds of *he formula can be prepared by a process which comprises a) reducing a compound of the formula '~'1 .
- 1 - :
P~
i,'l, , .~,, ~, , , . , . . , , :: .. , . : .
. , .. : , . :
: ~ , , . . . ~ . :
'.! R6 '~
;CH = C - NO I I
!,. 1 2 '1l Rl ~ \ :
R2 ~t ~, ~
~. N ~ -.::: :
,. 3/ \ 4- :-wherein Rl, R2, R3, R4 and R6 have the above given definition, to the forma-tion o a compound of the formula:I, wherein R5 is a hydrogen atom; ~. . .
b) reducing a compound of the formula :
~. R6 '"' ICH C N2 .
'1 2 = ~
~'! R3' \ R4/ .. ~ .
,,,,~ ~; .
.; ~
wherein Rl, R2, R4 and R6 have the above given definition and R3 is a lower ~ .
il;; aliphatic acyl group or a benzoyl group, to the formation of a compound of ~ : the formula I wherein R5 is a hydrogen atom;
."~ c) halogenating a compound of the formula . ;
; ~1 R6 Rl~
.¦ N
R R
wherein R3, R4, R5 and R6 have the above given definition and e1ther R or R
- 2 - :
'~` ' -, '. :
.. ~, . .' ' .
1~ ~3 i1 or both are hydrogen, to the formation of a compound of the formula I wherein Rl or R or both are a halogen atom, or - d) hydrolyzing a comyound of the formula ::
.. . .
; R6 CH~ - C - NH - Z
,~: 15 ' R2 ~J
: ~ -N
;. ~ R3 R4 wherein Rl, R2, R3, R4, R5 and R6 have the above given definition and Z is a lower aliphatic acyl group, to the formation of a compound of the formula I
" :.
wheTeafter the compound obtained in any of the methods a) to d) is con~erted -~e : ~to a pharmaceutically acceptable salt thereof and/or converted to a substan-tially pure isomer thereof. :
x~: 10: According to the present invention thére is provided compounds :
r~ g R R4 ' : wherein Rl and R2 are ~he same or different and each represents a hydrogen . ~ ~ atom, a lower alkyl group or a halogen atom; X represents either (i) a group R6 R6 : . ~ --CH=C-N02 or (li) n group - CH2-C-NH-Z, in which R5 represents a hydrogen atom;
or a methyl group, R6 ~s a lower alkyl group and Z is a lower allphatic acyl ~, group, R represents a lower alkyl group or a benzyl group and R4 represents i:, :
:~ : - , ~ 3 . ~ , . .
:,- ~ . .
- ~ ,. :
,. .. . .
~ 7~3~l3 ~:
a lower aIkyl group, a benzyl group or a -CH2CH2CH2 bridge connected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that Rl and/or R2 represents :
a lower alkyl group or a halogen atom when either (a) X is a -CH=C-N02 and R and R4 both represent a methyl or ethyl group or (b) X is a -CH2-C-NH-Z group as hereinbefore defined and R is :
R5 ;~
a methyl group, R4 is a methyl group, and R5 represents a hydrogen :
atom, and a process for their preparation. . : :
; This invention also relates to a process for the preparation of a compound conforming to the general formula:
,, .
N \ , R R .
herein Rl and R2 are the same or different and each represents a :. :
hydrogen atom, a lower aIkyl group or a halogen atom; X represents either (i) a group -CH--~-N~2 or (ii) a group -CH2 C ~H-Z, in ~ ~ which R5 represents a hydrogen atom or a methyl group, R6 is a lower :~
.:~ alkyl group and Z is a lower aliphatic acyl group, R represents a .
:~ lower alkyl group or a benzyl group, and R4 represents a lower~aIkyl ;i.l~ group, a benzyl group or a -CH2CH2CHz brldge connected to the~phenyl ring in the ortho-position relativ~ to the N-substituent, with the provisos that R1 and/or R2 represents lower aIkyl group or a .
halogen atom when either (a) X is a -CH=C-NO2 and R and R --~-. :
~`- : . : . . . .
.
`:
~ .
- 4 ~ ;
~, ' '. ' ' ~L~)7;~:13 ; . ~' ,.
lR6 - both represent a methyl or ethyl group or (b) X is a -CH2-C-NH-Z group as hereinbefore defined and R is a methyl group, R is a methyl group and R5 represents a hydrogen atom which comprises either~
~a) reacting an aldehyde of the formula III:-: CHO
Rl ~ :
I R2 ~
~/" '' ' ' \~
N
R \R4 wherein Rl' R , R4 and R are as deflned above with a nitroalkane of ~he formula: .
R CH2N02 : -~
: . . .
: wherein R6 is as defined above; or ~b) reacting a compound of the formula: ~
CH-CH-R5 ~ :
R
: ~ N
. R R
, :.
a compound of the formula:
~: R6 ; CH=C-R5 ' 1 1 :~ R ~ ~ \
R ~
; ~ " .
N
: : `
~ - 4a -.... . .. . .
~..CII'7;~13 wherein R, Rl, R2, R4, R5 and R6 are as defined above, with an alkali metal cyanide or nitrile.
Illustrative examples'of radicals included in the above defini-tions are ' lower alkyl group: methyl, ethyl, n-propyl and isopropyl ' halogen atom: chlorine, bromine, iodine-and fluorine. ' By the expression "lower alkyl group" in this application is to be under- ~" ' stood alkyl groups with 1 to 5 carbon atoms, inclusive.
The new compounds of formula I may be used therapeutically as '' 10 the racemic mixtures of (+) and (-)-forms, which are obtained by synthesis. :
They may also be resolved into the corresponding optically active modifications ~
,' which, likewise, may be used in therapy. These compounds may be administered ' ,~ in the form of free bases or their salts with non-toxic acids. Some typical i examples of these salts are the hydrobromide, hydrochloride, phosphate, " ~ ~ sulphate, citrate, tartrate.
In clinical practi~ce the above compounds of formula T will nor-~'' mally be administered oral,ly, rectally or by injection, in the form of phar-~ ~ :
maceutical preparations comprising the active ingredient either as a free " 1 ~ ' ~ ' -, ' : ~ ' '"' ~ ~ ,' :' .'"~ - . .
' . .
.
~" , " . " ' ' .
.:"~
",~ . i, .
. ~ .'. . :'' : .
' ~ :
base or as a pharmaceutically acceptable non-toxic, acid addition salt, e.g.
- the hydrochloride, hydrobromide, lactate, acetate, sulphate, sulphamate and the like in association with a pharmaceutically acceptable carrier. Accor-dingly, terms relating to the novel compounds of this invention whether { generically or specifically are intended to include both the free amine base and the acid addition salts of the free base, unless the context in which such terms are used, e.g. in the specific examples would b~ inconsistent with the broad concept. The carrier may be a solid, semisolid or liquid diluent or capsule. These pharmaceutical preparations constitute a further aspect of this invention. Usually the active substance will constitute between 0.1 and 95 % by weight of the preparation, more specifically between 0.5 and 20 %
~ by weight for preparation intended for injection and between 2 and 50 % by ', weight for preparations suitable for oral administration.
I To produce pharmaceutical preparations contaln m g a compound of I formula I in the form of dosage units for oral application, the selected - compound may be mixed with a solid pulverulent carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, or gelatine, and a lubricant such as , magnesium stearate, calcium stearate, polyethylene glycol waxes, and the like, ,f' 20 and then compressed to form tablets. If coated tablets are required, thecores, prepared as described above, may be coated with a concentrated sugar solution which may contain, e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a lacquer dissolved in a readily volatile organic solvent or mixture of organic solvents. ~-Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances of different amounts of the active compound.
For the preparation of soft gelatine capsules (pearl-shaped closed capsules) consisting of gelatine and for example, glycerol or similar closed capsules, the active substance may be admixed with a vegetable oil.
1 _ 5 _ ~', .
j :~
.
.,, . .:. : ~ .
... . . . . . .
.~
~ ~t~ 3 Hard gelatine capsules may contain granulates of the active substance in combination with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches ~e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine.
Dosage units for rectal application can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with uegetable oil or paraffin oil.
~ iquid preparations for oral application may be in the form of syrups or suspensions for example, solutions containing from about 0.2 % to about 20 % by weight of the active substance herein described, the balance being sugar and a mixture of ethanol, water, glycerol, and propyleneglycol~
Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent.
.. ; .
Solutions for parenteral applications by injection can be prepar-! ed in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5 % to about 10 % by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage -unit ampoules.
Suitable peroral doses of the compounds of the invention are 2-20 mg preferably 5-15 mg given 1 to 3 times a day, preferably 2 times a day.
The preferred compounds of formula I have the formulae ~ -,.' ., ~, :.
":''.
; ;'',, :
'1 .
;
... .
,j: ~i, , - . :
~,:, . ,j , :, .
` ~'7;~9~3 .`~
: 7 3 1 3 ~_-;IH2 CH-H
H
~` \ CH
C~3 3 CH3 CH3 ^ : Preferably these compounds 1~ill be prepared and used in the form of their ,:~ dihydrochloride salt.
.....
:i Methods_of_preparation ,:
. Reduction of a substituted ~-nitrostyrene of the formula ,, I ~
R3 / \ R4 i~
wheTein R ~ R2, R3~ R4 and R are as previously described~ to the formation~of:
a compound of the fo~mula I wherein R5 is a hydrogen atom. ~ :
; The red~ction can be effected by means of an appropriate reducing ~j 10 agent such aslithium aluminium hydride or by catalytic reduction~ or by other ~.
:known reducing agents. ~ :
B. Reduction of a compound of the fo~mula~
R :
,i ~ R3 \ R4 ,,:, ;: ~ :
: .
, :: - 7 :, ~ :
:~
::, , .::
.. . .
~L~7;~9~3 , ~Yherein R1, R-, R~ and R arc as previou~ly ~scrlbcd and R3 is a lower ~liph-atic acyl group or a benzoyl group to the formation of a compound of thc for-mula I wherein R5 is a hydrogen atom.
By thc eYpression "lower aliphatic acyl group" in this application lS ~0 oe understood aliphatic acyl groups R~~-wherein R is a hydrogen atom or an all~l group which contains 1 to 4 carbonatoms inclusive.
,~ n lustrative examples of lower aliphatic acyl groups are formyl~
., ~
acetyl, propionyl, butyryl, isobutyl and valeryl.
10C. Direct halogenation of a compound of the formula Rl R ~ 5 R ~ ~
T
i ; N
R3 / \ R4 ; wherein R3, R4, R5 and R are as previously described and either R or R or ; both are hydrogen~oftheformatlon of a compound of the formula I wherein R1 or R or both are a halogen atom.
;.i . :
D. Hydroly~ing a compound of the form~a ~ R6 ,,.'i ~ ' I . ' ~1 ~ CH2-C~NH-Z
R ~ S
~",, ~
.s ~
whcrein R ~ R , R3, ~ , R5 and R are as prcviously described and Z is a lower alipha~ic acyl group as defined on page 5~ to the formation of a compound of ;~
the formula I.
The llydrolyzation is performed with a strong mineral acid.
Pre~a~ation of Intermediates A. For the preparation of the compounds of the formula I wherein R5 is a hydrogen atom it has been found that a compo~md of the formula C}~C--NO
R ~
: R2 ~ IJ II
': ~/~`\
R3" \ R4' wherein Rl and B2 are the same or different and each represents a hydrogen a~om, a lo~er alkyl group or a halogen atom, R3 represents a lower alkyl group, a benzyl group, a~lower aliphatic acyl group or a benzoyl group, R4 re-presents a hydrogen atom, a lower alkyl group, a benzyl group or a CH2CH2CH2-bridge oonne~ted to the phenyl ring in ortho-position relative to the N-sub-stituent and R represents a lower aIkyl group, provided that R and/or R re-presents a lo~Yer alkyl group or a halogen atom when R3 and R4 both represent a methyl or an ethyl group or when R3 represents an acetyl group and R4 a hydrogen atom, is a valuable starting material.
The compounds of the formula II are prepared as outlined below '., R6 .'~1 1 1 CHO CH=C-~02 ~1~ , R2~
R3" \ R4 CH3COONH4 ~3" \ R
III II
' ' ' .
~073~3 ~ :
Thc intermediatc nitrostyrenes of the formula II werc prcparcd by a procedurc involving condensation of the obtained aldchydes with exccss nitro-al~ane, pre~erably in a suitable solvent, as for instance n-propyl alcohol, ethanol, acetic acid etc., in the presence of a base e.g. ammonium acetate.
Aldellydes of formula III ~herein ` R~ = R~ represents a lo~ier alkyl group or a benzyl group, and R~ represents a hydrogen atom, a lo~ier alkly group, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl ring in ortho-position relative to the N-substit~ent are prepared in a step involving the formylation of the substituted anil;ne according to the Yilsmeyer Haack reaction:
~ ~ R ~
,~ ~" i ,1 -i{~ ~ R3 R¢ R3i \ R4 The formylation is effected by using a mixture of dimethylformamide a phosphorus oxychloride. Alternatively the preparation is achieved by using ,.
a n~xture of phosphorus tribromide and dimethylformamide (Acta Pharm. Suecica 7, 87, lg70)~
"1:
Compounds other than dimethylformamide ~hich may serve as the form-~, j:, :
ylation agent are for instance N-methylformanilide or formamide. As catalysts ;~
,1~ other than phosporus oxychlorideand phosphorus tribromide may be used for in-stance, thionyl cliloridc, phosgene or aluminium chloride.
~; 20 B. For the preparation of the compounds of the formula I it has been found that a compound of the formula ` J :~
,, . ~ . .
I.j ,.~, ~ .
'' '' ' --10--~ ' ' j ~, ~ . ' `
' ,, ' , , ' .. . .' .. ,, ' , ~.'. ', '', ' , ' ~; . ' ', , ' ' ' ~ . ' ' ~ , . ' .'' ' . . , ~,` . ; . ' ' '" ~ , . , . , ' ' , . . .
~'739~3 R1 C~12--C~ Z
N~
R3 / \ R4 ; ~ or a salt thereof, wherein R and R2~are the same or different and each re-,, presents a hydrogen atom, a lower alkyl or a halogen atom, R~ represents a oYer ialkyl gr~up or a benzyl group, R4 represents a hydrogen atom, a lo~er aIkyl ~roup, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl r1ng ln ortho-position relative to the N-substituent, R5 represents a hydrogen atom or a methyl group, Ru is a lol~er allcyl group, and Z is a lower aliphatic acyl~group, pro~ided t~hat~R1 andjor R represents~a lo~er aIkyl group or a~
halogen atom when R3 is a methyl group,~R4 is a methyl group and R5 represents 10 ~ a ~ydrogen atom is a val~able starting ma*erial.
The compounds of the formula n can be prepared according to the reaction sequence i,l~ : .
~ 1 : ~ ~ : , ., ~LO734313 OH R
R ~ \ Ch~( ~ R2 ~ J
)2) H O, H I alkali metal , 2 / N\ ~ cyanide or . ~ R R R3 \R4 nitrile + . ' H
.,~ \ ~ . . .
; R
R R3 \
'r'' CH=C-R5 alkali meta R2 ~ ~ " cyanide or '~ `r' ~ nitrile R3 \R¢ H
herein R1~ R ~ R3~ R4, RS, R and Z have the previously given definition and '~ ~ is a bromide, chloride or iodide ion.
, I :
The aldehyde (prepared as described above~ is treated with the Gri~nard reagent and the obtained alcohol is either directly converted to the amide IV by reaction with an a~cali metal cyanide or a nitrile in the presence ~ of a strong acid~ e.g. sulphuric acid or via the dimcthylvinyl compound which ''?,~l~ 10 is reactcd with an a~cali motal cyanide or a nitrlle in the prescncc of a ~ -strong acid, e.gO sulphuric acid to the formation of the amide compo~md.
':'~~; ' ''"
~, , .
.
',,',,;~ , " ` ' .
`~ -12-;` . ::
,!, .: , . ' . : ~ . ' , . ' ' ' ' ' ~ 73~13 E~am~les Prcnaration of startinr material~
--E~amplc 1. N N-Dimeth~1-3-methyl-4-(2-nitropro~envl)aniline (a) 4-Dimcthvlamino-~-methYlbensaldehvde ~5 ml of phosphorus oxy-chloride is added dropwise while stirring and cooling in an ice bath to 145 ml of di~ethylform~mide. To this cooled solution is added by portions 67.5 g of N,~-dime~hyl-m-toluidine. After addition the mixture is heated on a steam bath for 2 hours. The dark l;quid is cooled and poured into 1.5 l of crushed ice. The solution is alkalized lYith sodium hydroxide. The crude, semisolid aldehyde (~9.6 g) which separatss is collected and purified by recrystalli~a-tion from isopropyl ether.
Yield: ~.6 g~ m.p. 65-6~ . Equiv. weight 163 (calc. 163.22) ~ he compound is also prepared as follows:
67.5 g of ~ dimethyl-m-toluidine is dissolved in 250 ~1 of dimethyl for~amide, and 3~ ml of phosphorus tribromide lS added dropwise with stirring and cooling in water. The temperature is not allowed to rise over 50 . The coRitIre is hea~ed for 1.5 hour on a steam bath and poured into appro~Yimately 1 of an ice ~ater mi~cture. The solution is alkalized l~ith sodium hydro-xide and the crude product (46.9 g3~ which separates, is recrystallized from isopropyl ether. Yield: 20.5 g, m.p. 63-65 . A second recrystallization from the same solvent gives 14.6 g of the pure aldehyde, melting at 65-66. ~ -(b) N,~T-Dimethyl-3-meth~1-4-~-nitropropenyllaniline. A solution of 28.0 g of 4-dimethylamino-2-methylben7aldehyde, 20 ml of nitroethane and ;
15 g of ammonium acetatc in 200 ml of 1-propanol is refluxed for 4 hours. The nuLYtur~ is thcn pourcd into 1 1 of ice ~atcr. The crudc compound (30.2 g) is purified by recrystaILizatlon from ~thanol-petroleum ethcr. Yield: 12.9 g~
m.p. 75-76.
Analysis. Calculated for C12H16N~02: C 65.~4, H 7.32~ N 12072.
Found: C 64.7, H 7.38, N 12.7.
.
:;
` ~ -13- ~ ~
1~3~13 ~ mDle ". ?~ D~ncth~ 3-chloro-4-("-nitroDror;en~)aniline A solution of 36.8 g of 2-chloro-4-dimethylaminobenzaldehyde, 18 ml of nitroethane and lS g of ammonium acetate in 150 ml of absolutc ethanol is refllLxcd for 2 hours. The m~xture is then poured into 1.5 l of water, lhere-upon the compo~nd separates as a viscous red oil, which cr~stalli3es on scrat- ~ -ch~n,. Recrysta71i-ation from ethanol yields 18.0 g of the compound, melting a~ 93-~4.
Analysis. &~cl~ated for CllH13CIN202: C 54.89, H 5.44, Cl 14.73, N 11.64.
Found: C ~4.2, H ~.4~, Cl 14.9, N 11.5.
~ 10 Exa~le 3. N~N-Dimethyl-3,5-dichloro-4-(2-~itropropenyl)aniline : ~.
(a) N,N-Dimethyl-3,5-dichloroaniline. To a mixture of 40.5 g of
'~` ' -, '. :
.. ~, . .' ' .
1~ ~3 i1 or both are hydrogen, to the formation of a compound of the formula I wherein Rl or R or both are a halogen atom, or - d) hydrolyzing a comyound of the formula ::
.. . .
; R6 CH~ - C - NH - Z
,~: 15 ' R2 ~J
: ~ -N
;. ~ R3 R4 wherein Rl, R2, R3, R4, R5 and R6 have the above given definition and Z is a lower aliphatic acyl group, to the formation of a compound of the formula I
" :.
wheTeafter the compound obtained in any of the methods a) to d) is con~erted -~e : ~to a pharmaceutically acceptable salt thereof and/or converted to a substan-tially pure isomer thereof. :
x~: 10: According to the present invention thére is provided compounds :
r~ g R R4 ' : wherein Rl and R2 are ~he same or different and each represents a hydrogen . ~ ~ atom, a lower alkyl group or a halogen atom; X represents either (i) a group R6 R6 : . ~ --CH=C-N02 or (li) n group - CH2-C-NH-Z, in which R5 represents a hydrogen atom;
or a methyl group, R6 ~s a lower alkyl group and Z is a lower allphatic acyl ~, group, R represents a lower alkyl group or a benzyl group and R4 represents i:, :
:~ : - , ~ 3 . ~ , . .
:,- ~ . .
- ~ ,. :
,. .. . .
~ 7~3~l3 ~:
a lower aIkyl group, a benzyl group or a -CH2CH2CH2 bridge connected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that Rl and/or R2 represents :
a lower alkyl group or a halogen atom when either (a) X is a -CH=C-N02 and R and R4 both represent a methyl or ethyl group or (b) X is a -CH2-C-NH-Z group as hereinbefore defined and R is :
R5 ;~
a methyl group, R4 is a methyl group, and R5 represents a hydrogen :
atom, and a process for their preparation. . : :
; This invention also relates to a process for the preparation of a compound conforming to the general formula:
,, .
N \ , R R .
herein Rl and R2 are the same or different and each represents a :. :
hydrogen atom, a lower aIkyl group or a halogen atom; X represents either (i) a group -CH--~-N~2 or (ii) a group -CH2 C ~H-Z, in ~ ~ which R5 represents a hydrogen atom or a methyl group, R6 is a lower :~
.:~ alkyl group and Z is a lower aliphatic acyl group, R represents a .
:~ lower alkyl group or a benzyl group, and R4 represents a lower~aIkyl ;i.l~ group, a benzyl group or a -CH2CH2CHz brldge connected to the~phenyl ring in the ortho-position relativ~ to the N-substituent, with the provisos that R1 and/or R2 represents lower aIkyl group or a .
halogen atom when either (a) X is a -CH=C-NO2 and R and R --~-. :
~`- : . : . . . .
.
`:
~ .
- 4 ~ ;
~, ' '. ' ' ~L~)7;~:13 ; . ~' ,.
lR6 - both represent a methyl or ethyl group or (b) X is a -CH2-C-NH-Z group as hereinbefore defined and R is a methyl group, R is a methyl group and R5 represents a hydrogen atom which comprises either~
~a) reacting an aldehyde of the formula III:-: CHO
Rl ~ :
I R2 ~
~/" '' ' ' \~
N
R \R4 wherein Rl' R , R4 and R are as deflned above with a nitroalkane of ~he formula: .
R CH2N02 : -~
: . . .
: wherein R6 is as defined above; or ~b) reacting a compound of the formula: ~
CH-CH-R5 ~ :
R
: ~ N
. R R
, :.
a compound of the formula:
~: R6 ; CH=C-R5 ' 1 1 :~ R ~ ~ \
R ~
; ~ " .
N
: : `
~ - 4a -.... . .. . .
~..CII'7;~13 wherein R, Rl, R2, R4, R5 and R6 are as defined above, with an alkali metal cyanide or nitrile.
Illustrative examples'of radicals included in the above defini-tions are ' lower alkyl group: methyl, ethyl, n-propyl and isopropyl ' halogen atom: chlorine, bromine, iodine-and fluorine. ' By the expression "lower alkyl group" in this application is to be under- ~" ' stood alkyl groups with 1 to 5 carbon atoms, inclusive.
The new compounds of formula I may be used therapeutically as '' 10 the racemic mixtures of (+) and (-)-forms, which are obtained by synthesis. :
They may also be resolved into the corresponding optically active modifications ~
,' which, likewise, may be used in therapy. These compounds may be administered ' ,~ in the form of free bases or their salts with non-toxic acids. Some typical i examples of these salts are the hydrobromide, hydrochloride, phosphate, " ~ ~ sulphate, citrate, tartrate.
In clinical practi~ce the above compounds of formula T will nor-~'' mally be administered oral,ly, rectally or by injection, in the form of phar-~ ~ :
maceutical preparations comprising the active ingredient either as a free " 1 ~ ' ~ ' -, ' : ~ ' '"' ~ ~ ,' :' .'"~ - . .
' . .
.
~" , " . " ' ' .
.:"~
",~ . i, .
. ~ .'. . :'' : .
' ~ :
base or as a pharmaceutically acceptable non-toxic, acid addition salt, e.g.
- the hydrochloride, hydrobromide, lactate, acetate, sulphate, sulphamate and the like in association with a pharmaceutically acceptable carrier. Accor-dingly, terms relating to the novel compounds of this invention whether { generically or specifically are intended to include both the free amine base and the acid addition salts of the free base, unless the context in which such terms are used, e.g. in the specific examples would b~ inconsistent with the broad concept. The carrier may be a solid, semisolid or liquid diluent or capsule. These pharmaceutical preparations constitute a further aspect of this invention. Usually the active substance will constitute between 0.1 and 95 % by weight of the preparation, more specifically between 0.5 and 20 %
~ by weight for preparation intended for injection and between 2 and 50 % by ', weight for preparations suitable for oral administration.
I To produce pharmaceutical preparations contaln m g a compound of I formula I in the form of dosage units for oral application, the selected - compound may be mixed with a solid pulverulent carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, or gelatine, and a lubricant such as , magnesium stearate, calcium stearate, polyethylene glycol waxes, and the like, ,f' 20 and then compressed to form tablets. If coated tablets are required, thecores, prepared as described above, may be coated with a concentrated sugar solution which may contain, e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a lacquer dissolved in a readily volatile organic solvent or mixture of organic solvents. ~-Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances of different amounts of the active compound.
For the preparation of soft gelatine capsules (pearl-shaped closed capsules) consisting of gelatine and for example, glycerol or similar closed capsules, the active substance may be admixed with a vegetable oil.
1 _ 5 _ ~', .
j :~
.
.,, . .:. : ~ .
... . . . . . .
.~
~ ~t~ 3 Hard gelatine capsules may contain granulates of the active substance in combination with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches ~e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine.
Dosage units for rectal application can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with uegetable oil or paraffin oil.
~ iquid preparations for oral application may be in the form of syrups or suspensions for example, solutions containing from about 0.2 % to about 20 % by weight of the active substance herein described, the balance being sugar and a mixture of ethanol, water, glycerol, and propyleneglycol~
Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent.
.. ; .
Solutions for parenteral applications by injection can be prepar-! ed in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5 % to about 10 % by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage -unit ampoules.
Suitable peroral doses of the compounds of the invention are 2-20 mg preferably 5-15 mg given 1 to 3 times a day, preferably 2 times a day.
The preferred compounds of formula I have the formulae ~ -,.' ., ~, :.
":''.
; ;'',, :
'1 .
;
... .
,j: ~i, , - . :
~,:, . ,j , :, .
` ~'7;~9~3 .`~
: 7 3 1 3 ~_-;IH2 CH-H
H
~` \ CH
C~3 3 CH3 CH3 ^ : Preferably these compounds 1~ill be prepared and used in the form of their ,:~ dihydrochloride salt.
.....
:i Methods_of_preparation ,:
. Reduction of a substituted ~-nitrostyrene of the formula ,, I ~
R3 / \ R4 i~
wheTein R ~ R2, R3~ R4 and R are as previously described~ to the formation~of:
a compound of the fo~mula I wherein R5 is a hydrogen atom. ~ :
; The red~ction can be effected by means of an appropriate reducing ~j 10 agent such aslithium aluminium hydride or by catalytic reduction~ or by other ~.
:known reducing agents. ~ :
B. Reduction of a compound of the fo~mula~
R :
,i ~ R3 \ R4 ,,:, ;: ~ :
: .
, :: - 7 :, ~ :
:~
::, , .::
.. . .
~L~7;~9~3 , ~Yherein R1, R-, R~ and R arc as previou~ly ~scrlbcd and R3 is a lower ~liph-atic acyl group or a benzoyl group to the formation of a compound of thc for-mula I wherein R5 is a hydrogen atom.
By thc eYpression "lower aliphatic acyl group" in this application lS ~0 oe understood aliphatic acyl groups R~~-wherein R is a hydrogen atom or an all~l group which contains 1 to 4 carbonatoms inclusive.
,~ n lustrative examples of lower aliphatic acyl groups are formyl~
., ~
acetyl, propionyl, butyryl, isobutyl and valeryl.
10C. Direct halogenation of a compound of the formula Rl R ~ 5 R ~ ~
T
i ; N
R3 / \ R4 ; wherein R3, R4, R5 and R are as previously described and either R or R or ; both are hydrogen~oftheformatlon of a compound of the formula I wherein R1 or R or both are a halogen atom.
;.i . :
D. Hydroly~ing a compound of the form~a ~ R6 ,,.'i ~ ' I . ' ~1 ~ CH2-C~NH-Z
R ~ S
~",, ~
.s ~
whcrein R ~ R , R3, ~ , R5 and R are as prcviously described and Z is a lower alipha~ic acyl group as defined on page 5~ to the formation of a compound of ;~
the formula I.
The llydrolyzation is performed with a strong mineral acid.
Pre~a~ation of Intermediates A. For the preparation of the compounds of the formula I wherein R5 is a hydrogen atom it has been found that a compo~md of the formula C}~C--NO
R ~
: R2 ~ IJ II
': ~/~`\
R3" \ R4' wherein Rl and B2 are the same or different and each represents a hydrogen a~om, a lo~er alkyl group or a halogen atom, R3 represents a lower alkyl group, a benzyl group, a~lower aliphatic acyl group or a benzoyl group, R4 re-presents a hydrogen atom, a lower alkyl group, a benzyl group or a CH2CH2CH2-bridge oonne~ted to the phenyl ring in ortho-position relative to the N-sub-stituent and R represents a lower aIkyl group, provided that R and/or R re-presents a lo~Yer alkyl group or a halogen atom when R3 and R4 both represent a methyl or an ethyl group or when R3 represents an acetyl group and R4 a hydrogen atom, is a valuable starting material.
The compounds of the formula II are prepared as outlined below '., R6 .'~1 1 1 CHO CH=C-~02 ~1~ , R2~
R3" \ R4 CH3COONH4 ~3" \ R
III II
' ' ' .
~073~3 ~ :
Thc intermediatc nitrostyrenes of the formula II werc prcparcd by a procedurc involving condensation of the obtained aldchydes with exccss nitro-al~ane, pre~erably in a suitable solvent, as for instance n-propyl alcohol, ethanol, acetic acid etc., in the presence of a base e.g. ammonium acetate.
Aldellydes of formula III ~herein ` R~ = R~ represents a lo~ier alkyl group or a benzyl group, and R~ represents a hydrogen atom, a lo~ier alkly group, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl ring in ortho-position relative to the N-substit~ent are prepared in a step involving the formylation of the substituted anil;ne according to the Yilsmeyer Haack reaction:
~ ~ R ~
,~ ~" i ,1 -i{~ ~ R3 R¢ R3i \ R4 The formylation is effected by using a mixture of dimethylformamide a phosphorus oxychloride. Alternatively the preparation is achieved by using ,.
a n~xture of phosphorus tribromide and dimethylformamide (Acta Pharm. Suecica 7, 87, lg70)~
"1:
Compounds other than dimethylformamide ~hich may serve as the form-~, j:, :
ylation agent are for instance N-methylformanilide or formamide. As catalysts ;~
,1~ other than phosporus oxychlorideand phosphorus tribromide may be used for in-stance, thionyl cliloridc, phosgene or aluminium chloride.
~; 20 B. For the preparation of the compounds of the formula I it has been found that a compound of the formula ` J :~
,, . ~ . .
I.j ,.~, ~ .
'' '' ' --10--~ ' ' j ~, ~ . ' `
' ,, ' , , ' .. . .' .. ,, ' , ~.'. ', '', ' , ' ~; . ' ', , ' ' ' ~ . ' ' ~ , . ' .'' ' . . , ~,` . ; . ' ' '" ~ , . , . , ' ' , . . .
~'739~3 R1 C~12--C~ Z
N~
R3 / \ R4 ; ~ or a salt thereof, wherein R and R2~are the same or different and each re-,, presents a hydrogen atom, a lower alkyl or a halogen atom, R~ represents a oYer ialkyl gr~up or a benzyl group, R4 represents a hydrogen atom, a lo~er aIkyl ~roup, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl r1ng ln ortho-position relative to the N-substituent, R5 represents a hydrogen atom or a methyl group, Ru is a lol~er allcyl group, and Z is a lower aliphatic acyl~group, pro~ided t~hat~R1 andjor R represents~a lo~er aIkyl group or a~
halogen atom when R3 is a methyl group,~R4 is a methyl group and R5 represents 10 ~ a ~ydrogen atom is a val~able starting ma*erial.
The compounds of the formula n can be prepared according to the reaction sequence i,l~ : .
~ 1 : ~ ~ : , ., ~LO734313 OH R
R ~ \ Ch~( ~ R2 ~ J
)2) H O, H I alkali metal , 2 / N\ ~ cyanide or . ~ R R R3 \R4 nitrile + . ' H
.,~ \ ~ . . .
; R
R R3 \
'r'' CH=C-R5 alkali meta R2 ~ ~ " cyanide or '~ `r' ~ nitrile R3 \R¢ H
herein R1~ R ~ R3~ R4, RS, R and Z have the previously given definition and '~ ~ is a bromide, chloride or iodide ion.
, I :
The aldehyde (prepared as described above~ is treated with the Gri~nard reagent and the obtained alcohol is either directly converted to the amide IV by reaction with an a~cali metal cyanide or a nitrile in the presence ~ of a strong acid~ e.g. sulphuric acid or via the dimcthylvinyl compound which ''?,~l~ 10 is reactcd with an a~cali motal cyanide or a nitrlle in the prescncc of a ~ -strong acid, e.gO sulphuric acid to the formation of the amide compo~md.
':'~~; ' ''"
~, , .
.
',,',,;~ , " ` ' .
`~ -12-;` . ::
,!, .: , . ' . : ~ . ' , . ' ' ' ' ' ~ 73~13 E~am~les Prcnaration of startinr material~
--E~amplc 1. N N-Dimeth~1-3-methyl-4-(2-nitropro~envl)aniline (a) 4-Dimcthvlamino-~-methYlbensaldehvde ~5 ml of phosphorus oxy-chloride is added dropwise while stirring and cooling in an ice bath to 145 ml of di~ethylform~mide. To this cooled solution is added by portions 67.5 g of N,~-dime~hyl-m-toluidine. After addition the mixture is heated on a steam bath for 2 hours. The dark l;quid is cooled and poured into 1.5 l of crushed ice. The solution is alkalized lYith sodium hydroxide. The crude, semisolid aldehyde (~9.6 g) which separatss is collected and purified by recrystalli~a-tion from isopropyl ether.
Yield: ~.6 g~ m.p. 65-6~ . Equiv. weight 163 (calc. 163.22) ~ he compound is also prepared as follows:
67.5 g of ~ dimethyl-m-toluidine is dissolved in 250 ~1 of dimethyl for~amide, and 3~ ml of phosphorus tribromide lS added dropwise with stirring and cooling in water. The temperature is not allowed to rise over 50 . The coRitIre is hea~ed for 1.5 hour on a steam bath and poured into appro~Yimately 1 of an ice ~ater mi~cture. The solution is alkalized l~ith sodium hydro-xide and the crude product (46.9 g3~ which separates, is recrystallized from isopropyl ether. Yield: 20.5 g, m.p. 63-65 . A second recrystallization from the same solvent gives 14.6 g of the pure aldehyde, melting at 65-66. ~ -(b) N,~T-Dimethyl-3-meth~1-4-~-nitropropenyllaniline. A solution of 28.0 g of 4-dimethylamino-2-methylben7aldehyde, 20 ml of nitroethane and ;
15 g of ammonium acetatc in 200 ml of 1-propanol is refluxed for 4 hours. The nuLYtur~ is thcn pourcd into 1 1 of ice ~atcr. The crudc compound (30.2 g) is purified by recrystaILizatlon from ~thanol-petroleum ethcr. Yield: 12.9 g~
m.p. 75-76.
Analysis. Calculated for C12H16N~02: C 65.~4, H 7.32~ N 12072.
Found: C 64.7, H 7.38, N 12.7.
.
:;
` ~ -13- ~ ~
1~3~13 ~ mDle ". ?~ D~ncth~ 3-chloro-4-("-nitroDror;en~)aniline A solution of 36.8 g of 2-chloro-4-dimethylaminobenzaldehyde, 18 ml of nitroethane and lS g of ammonium acetate in 150 ml of absolutc ethanol is refllLxcd for 2 hours. The m~xture is then poured into 1.5 l of water, lhere-upon the compo~nd separates as a viscous red oil, which cr~stalli3es on scrat- ~ -ch~n,. Recrysta71i-ation from ethanol yields 18.0 g of the compound, melting a~ 93-~4.
Analysis. &~cl~ated for CllH13CIN202: C 54.89, H 5.44, Cl 14.73, N 11.64.
Found: C ~4.2, H ~.4~, Cl 14.9, N 11.5.
~ 10 Exa~le 3. N~N-Dimethyl-3,5-dichloro-4-(2-~itropropenyl)aniline : ~.
(a) N,N-Dimethyl-3,5-dichloroaniline. To a mixture of 40.5 g of
3.5-dichloroaniline and 62.0 g of sodium hydrogen carbonate in 200 ml of 5b %
aq~eolts dio~ane is added dropwise with stirring and cooling in ice 60 ml of ",: , .
f ~ethyl-s~ ate (2 h). 100 ml of 30 % sodium hydroxide soIution is then add~d and the mlx-ture is refluxed for 1 hour. After filtration the solution ~}~ is extracted ~lith ether. The extracts are dried oYer anhydrous sodium sul-phate and the solvent is evaporated. The residue is recrystallized from meth~
a~ol.
; Yield: 16.~g, m.p. 53-~ . Equlv. :~-eight 193.5 (calc. 190.08).
,j 20 (b) ~,o-Dichloro-4-dimethylaminobenzaldehyde. 9 ml of phosphorus '~ oxychloride is added dro~ise while stirring and cooling in ice to a solution ,1 ~f 19.0 g of N~N-dimethyl-3,5-dichloroaniline in 29 ml of dimethylformamide.
,1 The mixture is heated for 1 hour on a steam bath and poured into ice. The sol-ution is alkalized with sodiu~ hydroxide and the crude product is filtered ~!1 Off.
'1 ':
Yield: 18.5 g, m.p. 152-157 . Thc compound is purificd by recrystallization `, from cthanol-dioxane.
Yield: 13.9 g, m.p. 167-168.
Analysis. Calculated for C9H9Cl2N0: C 49.56, H 4.16, Cl 32.51, N 6.42, .
- . .
; ' `` ~U~;'3~3 ~
0 7.3~. Found: C ~9.~, H ~.25, Cl 32.6, N 6.77, 0 7.~6.
~ c) N,N-Dimethyl-3,5-dichloro-4-(2-nitropropenyl)aniline. A sol-ution of 13.9 g 2,6-dichloro-~-dimethylaminoben_aldehyde, 7 ml of nitroethane and ld.0 ~ of ammonium acetate in 100 ml of 1-propanol is refluxed for 24 hollrs. The ~DLYture is then poured into 1 llof ice water. The precipitate is ~; filtered off and s~ashed l~ith water. Yield: 16.8 g, m.p. 105-110. Recry-, ....................................................................... .
stalli3ation from a~ueous ethanol gives 14.4 g of the analytically pure pro-duct~ melting at 113-114 .
Analysis. Calculated fior ~IlHl2Cl2N202: C 48.02, H 4.40~ Cl 25.77~ N 10.18, 0 11.63. Found: C 47.8~ ~ 4.43~ Cl 26.1~ N 9.95~ 0 11.6.
,:
Example 4. N-~lethvl-6-f2-nitropropeny~ 2~3~4-tetrahvdroquiniline ~ la~ N-~lethvl-1,2,3,4-tetrahvdroauinoline. To a mixture of 100 g of ,1 ~ 1, 2, 3, 4_tet~ahydroquinoline and 100 g of sodium hydrogen carbonate~in 600 ml of ~0 3 aqueous dioxane is added dropwlse with stirring and cooling in ice 100 ~1 of dimethyl sulphate (2 h). After the addition the mixture is stirred ` o~er night at room temperature. 200 ml of 30 % sodium hydroxide solutlon lS
then added and the mixture is refl~Ked for 1 hour. After filtration the sol~
uti~n is ~xtracted with ether. The extracts are dried over anhydrous sodium 3 ~ ~ sulphate and the solvent is evaporated. The residual oil (63.2 g) is dlstill- -ed~ Yield: 50.~ g, b.p. 10o-110 /10 mm. Equiv. weight 140 (calc. 147.22).
(b) 6-Formyl-1-methyl-1 2,3,4-tetrahydroquinoline. 31 ml of phos-,, I , - .: - , phorus oxychloride is added dropwise while stirring and cooling in ice into -100 ml of dimethylformamide. To the stlrred and cooled solution is added by ~,:.: :
portions 50.0 6 of ~-methyl-1,2,3,4-tetrahydroquinoline. After the addition ~! the mixture is he~ted on a steam bath for 1 hour. Tho liquid is coolcd and ~: , . .... - .. .
~ po~red into ~ 1 of cr~lshed ice. The sollltion is alkaliz6d with sodi-~ hyd~o- ~ -'~ xidc and extracted with ether. The extract is dried over anhydrous sodi~ sul-; phate and the solve m evaporated. The residual oil is distilled.
~ Yield: ~ 47.4 g, b.p. 175-178/6 mm. Equiv. weight 178 (calc. 175~23)o :i; ! ' ~ 15- ~
.
(c) ~-~tcth~1-6-(~-nitro~ro~cnvl~ 2~ tctrahvdro~uinolinc A
solution of 17.1 g of 6-formyl-l-methyl-l,2,3,4-tetrahydroquirloline, 24 ml of nitroethane and 20 ~ of ammonium acetate in 200 ml of l-propanol is refluxed ~or 5 hours. The nLL~ture is then poured into 1 1 of ice water. The precipit-at~d oil is e~tracted ~.~ith ether and dried with anhydrous sodium sulphate.
Evaporation of the solYent gives 54.8 of a dark yello~ oil~ which~ ho~ever~
. .
- ~ould not be recrystalli~ed. The product is used directly, without further s~ - purification, in the subsequent step.
; ~xam~le 5. N,N-DimethYl-3-bromo-4-(2-nitro~ro~envl)aniline ., .
~ 10 (a) 2-Bromo-4-dimethvlaminoben~aldehvde. 14.5 ml of phosphorus I
,~ cxychloride is added dropwise ~hile stirring and cooling to a solution of 31.6 g of N~N-dimethyl-3-bromoaniline in 46 ml of dimethylformamide. The mix-~ ,. . .
; ture is heated ~or 1 hour or. a steam bath and poured into ice. The solution is alkali~ed ~ith sodiu~ hydroxide. The precipitate is~filtered off and recry "~
~ stall~3ed from aqueous ethanol. Yield: 19.6 g~ m.p. 81-82 .
I :i, ~ , Analysis. Calc~lated for C9HlOBrNO: C 47.39~ H 4.42~ Br 35.04~ N 6.14 O 7.01. Found: C 47.1~ H 4.38~ Br 35.0~ N 6.11~ 0 7~40.
) N,N-Dimeth~1-3-bromo-4-(2-nitro~ropenvl~ aniline. A solution of 19.0 g of ~-bromo-4-di~ethylaminoben aldehyde~10 ml of nitroethane and 15 ~
of ammonium acetate in 100 ml of l-propanol is refluxed fqr 7 hours. The mix~
ture is then poured into 1 1 of ice water, The precipitate is filtered off and purified by recrystallization from aqueous ethanol. Yield~ 10.2 g~ m.p.
il Analysis. Calculated for CllH13BrN202: C 46.33~ H 4.59~ Br 28.03~ N 9.82 11.22~ Found: C 45.9~ H 4.57~ Br 28.0~ N 9.63~ 0 11.3.
... . .
~ amplc 6. N-~a,a-dimothY_-~-(4-dunethylami~lophenyl)cthyllacctamide ;~;` 9.2 ml of acctonitrilo is addcd drop~ise at room temperature to a stirred solution of 18.5 ml of concentrated sulphuric acid in 140 ml of acctic ~ . . . .
~ acid. 30.6 g of N~N-dimethyl-p-2~2~-dimethylvinylaniline is thcn added and .,;, ~ ~ ' "' '. ' ' ~16--,`, ~, . -: . ' ~0735~3 ,;
~
the mLL~ture is hcatcd and stirrcd for l ho~lr ~t 70. The liquid is pollrcd into crushed ice and thc nULY~UrC is ncutrali_cd ~Yith sodium hydroxidc (pH 6).
The crllde compolmd (29.3 g) is filtercd off and purified by rccrystallization from ethanol ligroin. Yield: 17.0 g, m.p. 156-157 . Analysis. Calculated for Cl~H~N20: C 71.75, H 9.46, N 11.96, 0 6.83. Found: C 71.4, H 9.4, .0, ~ 6.9.
E~a~ple 7. N.~-Dlmeth~1-3-chloro-4-(2-nitro-t-butenvl)aniline A solution of 36.8 g of 2-chloro-~-dimethylaminobenzaldehyds, 25 ml~
of l-nitropropQne and ~0 g of am~onium acetate in 150 ml of l-propanol is re-flu~ed for 15 hours. The ~ixture is then ~oured into 1.5 1 of water ~hereupon ~- the compound separates as a viscous red oil. Recrystallization t~ice from aqueous acetic acid yields 5.0 g of the compound, melting at 90-91.
~1 ." . . . .
, . . .
Analysis. Calculated for C~2~15ClN202: C 56.58, H 5.94, U 13.92, N 11.00~ ~ -0 12~56. Fo~nd: C 56.8, H 5.6, Cl 14.0, N 10.9.
Pre~a~ation of end co~rounds ~ -E~ample 8. 2-~tethyl-4-dimethylamino-~-methylphenetllylaminedihydro-,, i . . .
~ chloride (~lethod A) _ ~
: ~., . ~ ~ . .
12.5 g of N~-dimethyl-3-methyl-4-(2-nitropropenyl)aniline in 150 ml of dry eth~r is added to a stirred mixture of 9.1 g ofl;thium aluminium hydride ! : :: : -I 20 in 200 1 of dry e*her at such a rate that thc solvent refluxes ~ently l~ithout : ~
:. - .
external heating. The m Lxture is stirred and refluxed for 5 hours. 50 ml of sa*urated sodium sulphate solu-tion is added droplYise with vigorous stirring and cooling in ice water. The nLLxture is filtered and the etheral solution dried orer anhydrous sodium sulphatc. Thc dihydroclilorldc is precipitated from th~ solution by the addition of ether saturatcd with hydrogon chlorideO The crude salt is purified by recrystallization from ethanol-isopropyl ether. -~
Yield: 12.6 g~ m.p. 205-207 . A second rccrystallization from the samc solr vent gives 11.0 g of thc compo~ld, mclting at 208-20~ .
, .................. . . . .
`1 ' ' . ' ' -.. . .
~739~1~3 E~amplc 9. ~-Ethylamino-a-mctllylphenctIIylall~LncdihydrocIiloride (~Icthod b~ _ ~
11.0 g of ~-~2-I~itropropenyl)acctanilidc dissolved in 150 ml of dry tetrah~-drofuran is added dropwise to a stirred miYture of 11.0 g of lithium alluniniu~ hydride in 200 ml of dry ether. Aftcr the addition the reaction m~-ture is stirred and refluxed for 4 hours. 60 ml of saturated sodi~lm sulphate solution is added carefully ~ri*h stirring and cooling. The mixture is filtered .... .
, and the etheral solution is evaporated. The residue is dissolved in dilute J
1 hydrochlo1ic acid and the solution is shaken t~ith ether. The acidic layer is :J ~ .
alkalized with sodium hydroxide and the solution is extracted tYith ether.
fter dr~ing ov2r solid sodiumi hydroxide the extract is evaporated. The re-~ idue is distilled to obtained 4.7 g of free base boiling at 97-100/0.03 mm.
;;~l . , 1 The free amine is converted to the dihydrochloride by dissolving the base in ,'~ ether and treatinig *he .solution with an excess of dry hydrogen chloride. Re-~, i, , ; crystalli~ation of the obta~ned precip1tate yields 4.8 g of the pure salt,~
melt~ng at 184-185.
E~ample 10. 2-Chloro-~ methylamino u-methylphenethylaminedihydro-chloride (Method A3 A solution of 12.0 g of N~N-dimethyl-2-chloro-4-(~-nitropropenyl)-aniline in 150 ml of dry tetraltydrofuran is added dropwise with stirring to ~-' i!
8.o g oflithilD aluminium hydride in 200 mI of dry ethor. After the add1tion the reaction m~ture is ref~u~ed for 5 hours. 40 ml of saturated sodium sul-phate solution is added by portions and the mixture is filtered. The filtrate ; i .1 , .
~ is dried t~ith anhydrous sodium sulphate and acidified ~Yith hydrogen chloride .. : . :.
1 in ether. The prccipitatc is removed by filtration and recrystaIlised from " ~ , , .
ethanol-isopropyl ethcr. Yicld: 9.3 g "n.p. 187-191 . A second rcc~ystalli_ zation from thc same solvent yiolds 8.1 g of the pure compo~md, mclting at 193-195.
~;.i ~ - ..
. .. . .
ample 11. 2~6-Dichloro-~-dimcthylamino-~-methylphencthylaminc dihxdrochloridc (~lethod A) A solution of 13.7 g of ~-dimethyl-3~5-dichloro-4-(2-nitropropenyl) aniline in 150 ml of dry tctrahydrofuran is added dropwise with stirring to 8.o ~ lithi~ aluminium hydride in 200 ml of dry ether. The m~xture is-then re~l~Y~d for ~ hours. ~0 ~1 of saturated sodium sulphate solution is aadéd dropwise and the n~Lxture is filtered. The filtrate is dried over anhydrous ; ' sodium sulphate and acidified with hydrogen chloride. The precipitated salt is filt~ed off and washed with ether. Yield: 15.2 g, m.p. 195-197 .;:The ~' ' .:- , product is recrystallized from aqueous ethanol-isopropyl ether. Yieidi" ~1.9 g, m.p. 199-200. ` ~"' '' ' ~ Example 12. 3-Bromo-4-dimethylamino-a-methylphenethylamine dihydro-chloride (~lethod C) ~
.~: .. .
To a mlxture of 2.51 g of 4-dlmethylamino-a-methy1phenethylamine di-bydrochloride and 5.0 g of anhydrous sodium acetate in 50 ml of acetic~acid is ~ -' added dro~iise with stirring a solution of 0.51 ml of bromine in 50 ml of~
1 ,': ~ . . ;~ :.- .
J~ acetic acid. The ~LL~ture is stirred at room temperature for 2 hours. The '~
solYent is evaporated and the residue dissolYed in 200 ml of water. The~sol- ' ution is alkalised with sodium hydroxide and extracted with ether. The~e~her extract is dried over anhydrous sodium sulphate and acidified with hydrog~n ,, I , ,. :
~j I ' ~ chloride in ether. The precipitate is filtered off and recrystallized fr~m F, . ,.
, ; ethanol-ethyl acetatc. Yield: 2.3 g, m.p. 190-191 . :~ ;
Examplo 13. 6-(2-Aminopropyl)-1-met'h~1-1,2,3,4-tetrahydroquinoline .: , . , , ,:
dihydrochloridc ~lethod ~) ' 1 , :. - ' '~ A solution of 11.~ g of crudo N-mcthyl-6-(2-nitroyropenyl)-1~2~3,4-'~ tctrahydroquinolinc in 150 ml of dry ethor is added drop~isc with stirrihg to `1: 8.o g of lithium aluminium hydridc in 150 ml of ether. The reaction mixture :
~ ~ is ref1~Yed for 4 hours. 40 ml oY saturatcd sodium sulphatc solution is ~ddcd `I dropwise and the mixture is filtered. The filtrate is acidified with hydrogen ~ -19-!1 : ~
- ~073~13 , cliloridc in cther. The precipitatcd syrupy product is dissolvcd in "50 ml of ~ater and al~ali:ed ~Yith sodium hydroYide. The solution is c~tractcd ~ith "
ethcr and thc e~*ract is dried over anhydrous sodium sulphate. The solvent is ~' evaporated and the residual o;l is distilled. Yield: 3.3 g, b.p. 135-L37 /-0.07 mm. The base is dissolved in cther and the dihydrochloride is precipita-ted fr~m the sol~ltioD by the addition of an eYcess hydrogen chloride in ether.
.. ~,.
The precipitated salt is recrystalli3ed from ethanol-isopropyl ether.
- Yield: 3.3 g, m.p. 221-222 .
~mple 14. 2-Bromo-~-dimethylamino--methylphenethylamine dihydro-chloride ~Method Al _ ;
, A solu*ion of 10.0 g of N,N-dimethyl-3-bromo-4-(2-nitropropenyl) ~' ,', a~iline in 100 ~1 of dry tetrahydrofuran is added dropwise ~ith stirring to 3:~ : 8.o g Qflithium aluminium hydride in 200 ml of dry ether. After the addition the rei2rtion D~nture is refllLYed for 4 hours. 40 ml of saturated sodium 'sul-phate solution is then added by portions a~nd the m~Yture is filtered. The ,~ , filtrate is aeidified ~ith hydrogen chloridF in ether. The precipitated syrupy product is dissolved in water. The solution is washed with ether and al~ali~-~L~ ~
i ed wi~h sodium hydro,Yide. The separa~ed oil is e~tracted with ether and the ,, ~
'' ~ ether e~tract is dried ovcr anhydrous sodium sulphate. The solution is acid- ,' ,' 20 ified with hydrogen chloride in ether and the semi-solid precipitatei is filter- ' ~ ~ ed off and recrystalIi~ed from ethanol-isopropyl ether. , s!~ ~ Yield: 8.2 g, m.p. 19~-196 . ~ , , ~ Example 15. 4-Dimethylamino-a, a-dimethylphenethylaminedihydro-,..
~ _ chloride (Method D) _ -,~ ~ A solution of 3.5 g of N-~a~a-dimethyl-~-(4-dimethylaminophenyl) . .,.j . .
othyl3acctamide in a nLLYtUre of 25 ml of watcr and 25 ml of conccntratcd hydro~ ,1 chloric acid isrcfllLycd for 16 hours. The solution is thcn evaporatcd under redured prcssure and the rcsiduc is recrystalli-ed twice from mcthanol iso-propyl ethor, Yièld: I.1 g, m.p. 239~5-250~5 , ,ji,. ~ ~ .
~ 20-... . .
~ .
.,:
:~ , f F~ - ~
~ 739~3 :
, In table 1 are gi~rcn data for some end compounds of this invention . ..
includina those described in EYamples 8-15.
In table 2 are gi~en data for some intermediates of this in~ention includin~ those described in EYamp1es 1-7. The products of this table, not e~emplified aboYe, a~e analogously prep~red. The intermediate oily nitro sompounds are used direc~ly ~ithout further purification.
.:
::
, ~ ' ~ ,': ': :
. . .
:, .,' :
: ':
:'~' ' ;: ' ,j , .
'.'~ ~ :,:.
:1: . .
':j~
;
:, .' .
, .:
. . .
-21- ~
:
::~L0'73~13 ~ ~ 0 t~ -1' trl _- _ tO IJ~ O C') ('I ~\ I./7 i~o IJ~ r~
U'0 j t~ t~ . U~ o c, o~ ~ ~ tn ~
~ ~ ~ j o o o l ~ - ~ ~ ~ - ~ ~ ~
t~ ~ It~ ,t~ t~ _~ oo ~ _~ Ico co It~'), . .
tn ~ ~ o ~ er ~ ~ .~ _ rl ~n !
.. U ~ t~ ~ ~ rJ ~ ~O ¦ In t _ ~ 1:
~ ~ O ~t j t~ t~l ~ o _~ o c~ ~ ~r I o _ o t~ `D O ~o t~l ' , ~:~ .. t~ t~ t~ ! O O t~ ~J ~ ~O O O 1~ cO ~D 00I tx~ CO co 5~ t~ ~S - O -- "
:~ , ~ ~~ co I oc 00 oo ~ I oO oo ~ ~ `D ~ t"~ t" u~
.~ .~ q~ ~ ~ ~o ~ t~l lIq ~ t~ ~ Jm ~O t~ ~ '! `' -I ~~ '` o r- o ~D t~ ,, o ~ ~
~ ~ ~ t~~17 tA A ~A ~ tA tn u~ n In oo ~ ~ ~o _ ~ ~ o C~ I Ln In ~t ' I ~1 r~ I h ~I I ~ I ~ I ~1 7-~ I ~t ~ ~ 1 1 ~1 O ;~ ' I h I .
~: _~ t~ ~ C¦ O ~ O ~ tn -- t ~ .~ ~ I ~ O ~ tl~ O C~
:~ _~ ~rl ~ C~ ~ '.-~ t'~ IJ C~ .
, ~ ~ ~ C> j C~C.~ ~ ~ ~ I ~~ C~ O
tl~ O--~ O ~, O--O _~ O -- O ~ O ~ O O ~> O--~ ~ ~ ' O ~
b . ~3 ~ . tJ ~, td P~ ~d ~ ~: ~ td ~ h td ~ ~ ~ ~ &. i td ~ j .': ~ h .C h C u i ~ b ~ O ' ~ O ~ 0 j ~ ~1 ~, O ' v S h b ' ~ f~
~ ~ s~ ~ ~ ¦ 0 ~ 0 P~ ¦ 0 ~ 0 ~ 1 0 ~¦ ~d ~1 0 td Cl ~ ~ i ~ G ~
~ II ~ I I 1 ¦ . , ~ VCC_~ ''-u'l~ ~ ",i t., ~ l I ml Iml ~dol l ~1 IIAI I
} ~ N ~ = ~ ct~ ~ m I `D ~ tn I I ~ ~ ~ ~, D l o~ ¦ ¦ ¦ ¦ ¦ ¦
-~ I f-i i U~, I ~o I I I
t~n~ ~ O . t'~ I o I t~ ~ o Y~ o~ N~ C~ ~ ~
Y ~ `J ~ N ~ ~
~ iY~ U lU lU ~ U 1~
~A l -- ¦
I N I I I I I :~
~ u~ ¦ u l u ¦ u ¦ u ¦ ~ ¦ u ! t~ ¦ u l ~ In l ~~;m I
~ I u~ 8~ lu~ lùo lu~ 18~ lu la~
~lj ~ x ~ 1~
I ~, ~u I= I~ lu I ~ 1 lu ' ~-2 2 - ~ ~
,`: ': : . : ' : : ' :
' . ' ,:` - ' : , ~ ' ':
:;,: - : : :
' . ' ~ f~
Lf073913 :;;
Iu~
VL~ ~ oci ~.
"~ cff ~ u7i f o .~ ~ tcff = M t~
X V ~
V ~--I V
1:~ ~ ~ V h ff ~ffl ~
f VI~ ~ff 3 :5 : ~ :
;-'{'~ ~V `f ¦ ~ r 1~ : N :
r~ 1, ; ~ `
~L0739~L3 R6 .. :
,, I ,.
,,., CH=C-~2 : : .
RZ ~ ~ ~ :
R31~ \ R4~ :
q ~
* R2 ~ ~311 R4 R M.p. C Described in : Example No.
3 ~ H : CH3 ~ CH3 CH3 75-76 1 (b) ; Z~ H ~ C ~ CH3 CH3. Oil tl'~U t.-- U t~U tr~
- V~3 2'5 ~"3 v H~ ~ N ~ 5 ~ C6H5cHz CH3 Oil 3-Cl ~ H : CH3 CH3 ~ CH3 ~93~94 ~ 2 3-Cl ~ ~-CL~ ~C~ ~ ~CH; ~;~ CH3 ~ 113-114 ~ 3 (c) :3-Br : H:~ : CH3 ~ ~ CH3 ~; ~ CH3~ 02-lO3 ~ 5:(b) Pharmacolo~ical tests r~ '.~ It is not possible by:cxperi~ental means to induce depressions in : laboratory animals.~ In ordcr to evaluatc a poss:ible anti-depressive~éffect~On new substances blochemical-pha ~ acological;~test methods~mu~st~be resorted to.~ ~
One~such~mcthod, which seems to ~ive~a good:indication~of~the~pote~tial anti~- :
depressive effccts of tho test substances, ls desoribcd ln~Europ.~J. Pharmacol,~:
17, 107, 197 This method involves thc measurcment of thc potentiation of the syndromes produced by 5-hydroxytryptophan (5-HTP) in a laboratory animal.
The lack of euphoric effects, that is lack of central stimulatory activity, is testcd by measuring the motor activity in mice after administra-tion of the test substance.
Potential anxiolytic activity is tested by measuring the antiag-gressi~ity in isolated mice after administration of the test substance. In *his t~st not amphetamine but Valium ~ - a well-kno~m anxio btic substance -' , is used as a reference.
; 10 5-~TP res~onse potentiation test Inhibition of the uptake of 5-HT potentiates the effects of adminis-tered ~-hydroxytryptophan (5~HTP) probably by increasing the amount of 5-HT at , the receptor. Three mice are gi~en the test drugs one hour (or 4, 24 hours) , before dl-3-HTP, 90 m~k~ i.v~ 5-~TP alone gives only a weak behavioural syn-drome cu* in pretreated mice there is seen a characteristic beha~ioural syn-drome, which somes within fi~e mlnutes: tremor, lordosis~ abduction of the hind1egs~ head-t~itches~
The a~sence or presence of respective syndrome is scored in groups ~
of ten ~ice. The compound was administered in at least five doses and the ~ -,, j , quantal responses were analysed by probit analysis and ED50 determined accord-ing to the method of Litchfield and Wilcoxon.
i ~
Motor activity in mice The explor~tory activitr of mice was recorded in a locomotion cage ~; in ~hich the movements were counted each time the animals cross-ci cuits an . :1 ¦~ elec~rical currcnt in thc bottom plate. Thc acti~ity was recorded for tcn ,':'1 ' ' ` , : , ~11 minutes onc hour after the administration of the d~lg. The animals were ;.1 i tested individuaIly. Groups of six mice were uscd and the micc were only uscd once. The activity was expressed in per ccnt of the acti~ity of control groups ran simultaneously.~ The compounds were administered in at least four doses.
., :
: , . ., . . - .: : : . ,,. ... , . .. , . ... . , . ,: , . . ...... .. . ....
:~10~3g~3 .
The increase ~+) or decrease (-) of the activity comparcd to control n~roups was determined from log dosc response cursres.
Ao~ressive behaviollr in mice ~ lale mice kept isol~ted for 3 weeks or longer develop an aggressive beha~iour s~-hen caged together. The method used follows that of ~'al~elli et al.
~Eur~p ~. Pharmacol. 2, t44, 1967), with -the exception that 2 mice were test-ed on each other. The ag,~ressiveness was scored during a S min test according .
to the followino~ schedule:
O the animals show no interest in each other except occasional nosing ;~ 25 frequent ~igorous nosing and tail rattling, the animals assume a fighting position and occasionally attack each other - no more ~ ~ -~;~ than 3-4 times in the 5 min perlod 5D tail rattling, powerful attacks - no more than 10 times in the test period ~ 75 the animals fo lo~r their partners~ attacking and blting for most 'i of the ti~e '~ ~ lOO;attacks over the entire period.
Controls ar~ministered with the solvent were tested~ the repeated testing~ did no~ influence on the aggressiveness. The animals were used for several e.~periments but ~ith interrals of at least one week.~ Groups of 10 mice were used.
ED50 is the dose which reduces the aggressi~reness score by 50 %.
~j ~ ' '.
~?1~`
S, ,. ~: : ' :, ~ 26- ~
"~
~)73~13 Table , Phar~acological effects of ~-aminoamphetaminc derivatiYes ;~ R _ ~ R
`:: ' 1' 11 R ~ ~ ~ ~
N
~: R3 1 \ R4 Compound~ : ~ Potentiation Motor Anti~
: ? ~6 of 5-HTP Activity aggressive .~: Rl : R R3 R4 R5 R ED ~ = increase behaviour :
, ~ 50 mg/kg _ -~decrease in mice ~::
i.p.0 = no~ effect ED50 mg/kg: ~ -. p .
Valium ~ 2.5 : A3ph-tanine >5 1 : . p-A~dn~amphetaDine ~: 11.5 ~
p-Chl~roa~phetaQine . ¦ 0.8~ 0.3 H ~ H C2~5 C2i~5 H~ CH3 2 ~ : 5-10 2-Cl CH3 CH3 H CH3 0.25 ~ _ : : :2:.5-5 :~
H~ ~ H ~ C2H5 H H CH3 1 1:.25 H~ -2-CH3 CH3 3 H ~ C1l3 0.6 ~ 2.5-5 H: 1~: C2H5:CH3 ~ ~I Clt3 0.7 ~5 ~ H~ 3-B~: CH ~ 1 ~5 ;f ~ ; 2-Cl ~ 6-Cl~ GH3 CH3 ~ CH3 0.1 - ~>5 H :~ ~: H~ ~ C113 -~2)3- ~ a ~1:.5 >5 2-Br C~l3 C~I C1~3 0.1 : i~
H::~ 11 CH3 C1~3C~l3 C~3 :~2.5 H Z-Cl CH3 CH3H C21i5~ 0.25 : ~ Not testcd, ~ue to inter~erence with motor activity ~: .
As can be seen from tho test ~alues o~ Table 3 thei tested:substances:: ;~
5~ diffcr considerably in actiYity from ampheeamine both qualitatively and quant-: itativ~ly. In contrast~to ampheta~ine thc:~tested compo-~ds:of:the invention strongly~potcntlato the 5-HTP response. Furthermore the tested c;ompounds lack ~ . .
the ~central stimulation which is pronounccd after amphotamlne and p-chloro~
- ~ r .
1~3~ ff , .
amphet~mine. The tcsted compounds rather givo a weak sedation. Thus, the potential antidcprcssive activity as indicated by the potentiation of o-H'rP
and the lack of central stimulatory activity may give the compoullds of this invention value as potential antidcpressive agents.
The tested compounds antagonize the aggressive behaviour of male mice which have been kept isolated for one month or more. Many of the com-'~ ~ pounds are at least as active as Valium in this test which may indicate that ,~ these compounds may have therapeutic value as anxiolytic compounds.
~1 " '.' ~' ..
.
~,,f~
f, :~: f ~!r tJ, f~
~' ~ ' ` ' ' `" "''' " ' ' ,', ' ' '~'~ 1 ~: ; ; :. :
! I; - - ' ., ': :
.! ', ~ ~ 28 ., . ~ , . . . , ~ .. , ~ . . : ,. . . . .. . .:
aq~eolts dio~ane is added dropwise with stirring and cooling in ice 60 ml of ",: , .
f ~ethyl-s~ ate (2 h). 100 ml of 30 % sodium hydroxide soIution is then add~d and the mlx-ture is refluxed for 1 hour. After filtration the solution ~}~ is extracted ~lith ether. The extracts are dried oYer anhydrous sodium sul-phate and the solvent is evaporated. The residue is recrystallized from meth~
a~ol.
; Yield: 16.~g, m.p. 53-~ . Equlv. :~-eight 193.5 (calc. 190.08).
,j 20 (b) ~,o-Dichloro-4-dimethylaminobenzaldehyde. 9 ml of phosphorus '~ oxychloride is added dro~ise while stirring and cooling in ice to a solution ,1 ~f 19.0 g of N~N-dimethyl-3,5-dichloroaniline in 29 ml of dimethylformamide.
,1 The mixture is heated for 1 hour on a steam bath and poured into ice. The sol-ution is alkalized with sodiu~ hydroxide and the crude product is filtered ~!1 Off.
'1 ':
Yield: 18.5 g, m.p. 152-157 . Thc compound is purificd by recrystallization `, from cthanol-dioxane.
Yield: 13.9 g, m.p. 167-168.
Analysis. Calculated for C9H9Cl2N0: C 49.56, H 4.16, Cl 32.51, N 6.42, .
- . .
; ' `` ~U~;'3~3 ~
0 7.3~. Found: C ~9.~, H ~.25, Cl 32.6, N 6.77, 0 7.~6.
~ c) N,N-Dimethyl-3,5-dichloro-4-(2-nitropropenyl)aniline. A sol-ution of 13.9 g 2,6-dichloro-~-dimethylaminoben_aldehyde, 7 ml of nitroethane and ld.0 ~ of ammonium acetate in 100 ml of 1-propanol is refluxed for 24 hollrs. The ~DLYture is then poured into 1 llof ice water. The precipitate is ~; filtered off and s~ashed l~ith water. Yield: 16.8 g, m.p. 105-110. Recry-, ....................................................................... .
stalli3ation from a~ueous ethanol gives 14.4 g of the analytically pure pro-duct~ melting at 113-114 .
Analysis. Calculated fior ~IlHl2Cl2N202: C 48.02, H 4.40~ Cl 25.77~ N 10.18, 0 11.63. Found: C 47.8~ ~ 4.43~ Cl 26.1~ N 9.95~ 0 11.6.
,:
Example 4. N-~lethvl-6-f2-nitropropeny~ 2~3~4-tetrahvdroquiniline ~ la~ N-~lethvl-1,2,3,4-tetrahvdroauinoline. To a mixture of 100 g of ,1 ~ 1, 2, 3, 4_tet~ahydroquinoline and 100 g of sodium hydrogen carbonate~in 600 ml of ~0 3 aqueous dioxane is added dropwlse with stirring and cooling in ice 100 ~1 of dimethyl sulphate (2 h). After the addition the mixture is stirred ` o~er night at room temperature. 200 ml of 30 % sodium hydroxide solutlon lS
then added and the mixture is refl~Ked for 1 hour. After filtration the sol~
uti~n is ~xtracted with ether. The extracts are dried over anhydrous sodium 3 ~ ~ sulphate and the solvent is evaporated. The residual oil (63.2 g) is dlstill- -ed~ Yield: 50.~ g, b.p. 10o-110 /10 mm. Equiv. weight 140 (calc. 147.22).
(b) 6-Formyl-1-methyl-1 2,3,4-tetrahydroquinoline. 31 ml of phos-,, I , - .: - , phorus oxychloride is added dropwise while stirring and cooling in ice into -100 ml of dimethylformamide. To the stlrred and cooled solution is added by ~,:.: :
portions 50.0 6 of ~-methyl-1,2,3,4-tetrahydroquinoline. After the addition ~! the mixture is he~ted on a steam bath for 1 hour. Tho liquid is coolcd and ~: , . .... - .. .
~ po~red into ~ 1 of cr~lshed ice. The sollltion is alkaliz6d with sodi-~ hyd~o- ~ -'~ xidc and extracted with ether. The extract is dried over anhydrous sodi~ sul-; phate and the solve m evaporated. The residual oil is distilled.
~ Yield: ~ 47.4 g, b.p. 175-178/6 mm. Equiv. weight 178 (calc. 175~23)o :i; ! ' ~ 15- ~
.
(c) ~-~tcth~1-6-(~-nitro~ro~cnvl~ 2~ tctrahvdro~uinolinc A
solution of 17.1 g of 6-formyl-l-methyl-l,2,3,4-tetrahydroquirloline, 24 ml of nitroethane and 20 ~ of ammonium acetate in 200 ml of l-propanol is refluxed ~or 5 hours. The nLL~ture is then poured into 1 1 of ice water. The precipit-at~d oil is e~tracted ~.~ith ether and dried with anhydrous sodium sulphate.
Evaporation of the solYent gives 54.8 of a dark yello~ oil~ which~ ho~ever~
. .
- ~ould not be recrystalli~ed. The product is used directly, without further s~ - purification, in the subsequent step.
; ~xam~le 5. N,N-DimethYl-3-bromo-4-(2-nitro~ro~envl)aniline ., .
~ 10 (a) 2-Bromo-4-dimethvlaminoben~aldehvde. 14.5 ml of phosphorus I
,~ cxychloride is added dropwise ~hile stirring and cooling to a solution of 31.6 g of N~N-dimethyl-3-bromoaniline in 46 ml of dimethylformamide. The mix-~ ,. . .
; ture is heated ~or 1 hour or. a steam bath and poured into ice. The solution is alkali~ed ~ith sodiu~ hydroxide. The precipitate is~filtered off and recry "~
~ stall~3ed from aqueous ethanol. Yield: 19.6 g~ m.p. 81-82 .
I :i, ~ , Analysis. Calc~lated for C9HlOBrNO: C 47.39~ H 4.42~ Br 35.04~ N 6.14 O 7.01. Found: C 47.1~ H 4.38~ Br 35.0~ N 6.11~ 0 7~40.
) N,N-Dimeth~1-3-bromo-4-(2-nitro~ropenvl~ aniline. A solution of 19.0 g of ~-bromo-4-di~ethylaminoben aldehyde~10 ml of nitroethane and 15 ~
of ammonium acetate in 100 ml of l-propanol is refluxed fqr 7 hours. The mix~
ture is then poured into 1 1 of ice water, The precipitate is filtered off and purified by recrystallization from aqueous ethanol. Yield~ 10.2 g~ m.p.
il Analysis. Calculated for CllH13BrN202: C 46.33~ H 4.59~ Br 28.03~ N 9.82 11.22~ Found: C 45.9~ H 4.57~ Br 28.0~ N 9.63~ 0 11.3.
... . .
~ amplc 6. N-~a,a-dimothY_-~-(4-dunethylami~lophenyl)cthyllacctamide ;~;` 9.2 ml of acctonitrilo is addcd drop~ise at room temperature to a stirred solution of 18.5 ml of concentrated sulphuric acid in 140 ml of acctic ~ . . . .
~ acid. 30.6 g of N~N-dimethyl-p-2~2~-dimethylvinylaniline is thcn added and .,;, ~ ~ ' "' '. ' ' ~16--,`, ~, . -: . ' ~0735~3 ,;
~
the mLL~ture is hcatcd and stirrcd for l ho~lr ~t 70. The liquid is pollrcd into crushed ice and thc nULY~UrC is ncutrali_cd ~Yith sodium hydroxidc (pH 6).
The crllde compolmd (29.3 g) is filtercd off and purified by rccrystallization from ethanol ligroin. Yield: 17.0 g, m.p. 156-157 . Analysis. Calculated for Cl~H~N20: C 71.75, H 9.46, N 11.96, 0 6.83. Found: C 71.4, H 9.4, .0, ~ 6.9.
E~a~ple 7. N.~-Dlmeth~1-3-chloro-4-(2-nitro-t-butenvl)aniline A solution of 36.8 g of 2-chloro-~-dimethylaminobenzaldehyds, 25 ml~
of l-nitropropQne and ~0 g of am~onium acetate in 150 ml of l-propanol is re-flu~ed for 15 hours. The ~ixture is then ~oured into 1.5 1 of water ~hereupon ~- the compound separates as a viscous red oil. Recrystallization t~ice from aqueous acetic acid yields 5.0 g of the compound, melting at 90-91.
~1 ." . . . .
, . . .
Analysis. Calculated for C~2~15ClN202: C 56.58, H 5.94, U 13.92, N 11.00~ ~ -0 12~56. Fo~nd: C 56.8, H 5.6, Cl 14.0, N 10.9.
Pre~a~ation of end co~rounds ~ -E~ample 8. 2-~tethyl-4-dimethylamino-~-methylphenetllylaminedihydro-,, i . . .
~ chloride (~lethod A) _ ~
: ~., . ~ ~ . .
12.5 g of N~-dimethyl-3-methyl-4-(2-nitropropenyl)aniline in 150 ml of dry eth~r is added to a stirred mixture of 9.1 g ofl;thium aluminium hydride ! : :: : -I 20 in 200 1 of dry e*her at such a rate that thc solvent refluxes ~ently l~ithout : ~
:. - .
external heating. The m Lxture is stirred and refluxed for 5 hours. 50 ml of sa*urated sodium sulphate solu-tion is added droplYise with vigorous stirring and cooling in ice water. The nLLxture is filtered and the etheral solution dried orer anhydrous sodium sulphatc. Thc dihydroclilorldc is precipitated from th~ solution by the addition of ether saturatcd with hydrogon chlorideO The crude salt is purified by recrystallization from ethanol-isopropyl ether. -~
Yield: 12.6 g~ m.p. 205-207 . A second rccrystallization from the samc solr vent gives 11.0 g of thc compo~ld, mclting at 208-20~ .
, .................. . . . .
`1 ' ' . ' ' -.. . .
~739~1~3 E~amplc 9. ~-Ethylamino-a-mctllylphenctIIylall~LncdihydrocIiloride (~Icthod b~ _ ~
11.0 g of ~-~2-I~itropropenyl)acctanilidc dissolved in 150 ml of dry tetrah~-drofuran is added dropwise to a stirred miYture of 11.0 g of lithium alluniniu~ hydride in 200 ml of dry ether. Aftcr the addition the reaction m~-ture is stirred and refluxed for 4 hours. 60 ml of saturated sodi~lm sulphate solution is added carefully ~ri*h stirring and cooling. The mixture is filtered .... .
, and the etheral solution is evaporated. The residue is dissolved in dilute J
1 hydrochlo1ic acid and the solution is shaken t~ith ether. The acidic layer is :J ~ .
alkalized with sodium hydroxide and the solution is extracted tYith ether.
fter dr~ing ov2r solid sodiumi hydroxide the extract is evaporated. The re-~ idue is distilled to obtained 4.7 g of free base boiling at 97-100/0.03 mm.
;;~l . , 1 The free amine is converted to the dihydrochloride by dissolving the base in ,'~ ether and treatinig *he .solution with an excess of dry hydrogen chloride. Re-~, i, , ; crystalli~ation of the obta~ned precip1tate yields 4.8 g of the pure salt,~
melt~ng at 184-185.
E~ample 10. 2-Chloro-~ methylamino u-methylphenethylaminedihydro-chloride (Method A3 A solution of 12.0 g of N~N-dimethyl-2-chloro-4-(~-nitropropenyl)-aniline in 150 ml of dry tetraltydrofuran is added dropwise with stirring to ~-' i!
8.o g oflithilD aluminium hydride in 200 mI of dry ethor. After the add1tion the reaction m~ture is ref~u~ed for 5 hours. 40 ml of saturated sodium sul-phate solution is added by portions and the mixture is filtered. The filtrate ; i .1 , .
~ is dried t~ith anhydrous sodium sulphate and acidified ~Yith hydrogen chloride .. : . :.
1 in ether. The prccipitatc is removed by filtration and recrystaIlised from " ~ , , .
ethanol-isopropyl ethcr. Yicld: 9.3 g "n.p. 187-191 . A second rcc~ystalli_ zation from thc same solvent yiolds 8.1 g of the pure compo~md, mclting at 193-195.
~;.i ~ - ..
. .. . .
ample 11. 2~6-Dichloro-~-dimcthylamino-~-methylphencthylaminc dihxdrochloridc (~lethod A) A solution of 13.7 g of ~-dimethyl-3~5-dichloro-4-(2-nitropropenyl) aniline in 150 ml of dry tctrahydrofuran is added dropwise with stirring to 8.o ~ lithi~ aluminium hydride in 200 ml of dry ether. The m~xture is-then re~l~Y~d for ~ hours. ~0 ~1 of saturated sodium sulphate solution is aadéd dropwise and the n~Lxture is filtered. The filtrate is dried over anhydrous ; ' sodium sulphate and acidified with hydrogen chloride. The precipitated salt is filt~ed off and washed with ether. Yield: 15.2 g, m.p. 195-197 .;:The ~' ' .:- , product is recrystallized from aqueous ethanol-isopropyl ether. Yieidi" ~1.9 g, m.p. 199-200. ` ~"' '' ' ~ Example 12. 3-Bromo-4-dimethylamino-a-methylphenethylamine dihydro-chloride (~lethod C) ~
.~: .. .
To a mlxture of 2.51 g of 4-dlmethylamino-a-methy1phenethylamine di-bydrochloride and 5.0 g of anhydrous sodium acetate in 50 ml of acetic~acid is ~ -' added dro~iise with stirring a solution of 0.51 ml of bromine in 50 ml of~
1 ,': ~ . . ;~ :.- .
J~ acetic acid. The ~LL~ture is stirred at room temperature for 2 hours. The '~
solYent is evaporated and the residue dissolYed in 200 ml of water. The~sol- ' ution is alkalised with sodium hydroxide and extracted with ether. The~e~her extract is dried over anhydrous sodium sulphate and acidified with hydrog~n ,, I , ,. :
~j I ' ~ chloride in ether. The precipitate is filtered off and recrystallized fr~m F, . ,.
, ; ethanol-ethyl acetatc. Yield: 2.3 g, m.p. 190-191 . :~ ;
Examplo 13. 6-(2-Aminopropyl)-1-met'h~1-1,2,3,4-tetrahydroquinoline .: , . , , ,:
dihydrochloridc ~lethod ~) ' 1 , :. - ' '~ A solution of 11.~ g of crudo N-mcthyl-6-(2-nitroyropenyl)-1~2~3,4-'~ tctrahydroquinolinc in 150 ml of dry ethor is added drop~isc with stirrihg to `1: 8.o g of lithium aluminium hydridc in 150 ml of ether. The reaction mixture :
~ ~ is ref1~Yed for 4 hours. 40 ml oY saturatcd sodium sulphatc solution is ~ddcd `I dropwise and the mixture is filtered. The filtrate is acidified with hydrogen ~ -19-!1 : ~
- ~073~13 , cliloridc in cther. The precipitatcd syrupy product is dissolvcd in "50 ml of ~ater and al~ali:ed ~Yith sodium hydroYide. The solution is c~tractcd ~ith "
ethcr and thc e~*ract is dried over anhydrous sodium sulphate. The solvent is ~' evaporated and the residual o;l is distilled. Yield: 3.3 g, b.p. 135-L37 /-0.07 mm. The base is dissolved in cther and the dihydrochloride is precipita-ted fr~m the sol~ltioD by the addition of an eYcess hydrogen chloride in ether.
.. ~,.
The precipitated salt is recrystalli3ed from ethanol-isopropyl ether.
- Yield: 3.3 g, m.p. 221-222 .
~mple 14. 2-Bromo-~-dimethylamino--methylphenethylamine dihydro-chloride ~Method Al _ ;
, A solu*ion of 10.0 g of N,N-dimethyl-3-bromo-4-(2-nitropropenyl) ~' ,', a~iline in 100 ~1 of dry tetrahydrofuran is added dropwise ~ith stirring to 3:~ : 8.o g Qflithium aluminium hydride in 200 ml of dry ether. After the addition the rei2rtion D~nture is refllLYed for 4 hours. 40 ml of saturated sodium 'sul-phate solution is then added by portions a~nd the m~Yture is filtered. The ,~ , filtrate is aeidified ~ith hydrogen chloridF in ether. The precipitated syrupy product is dissolved in water. The solution is washed with ether and al~ali~-~L~ ~
i ed wi~h sodium hydro,Yide. The separa~ed oil is e~tracted with ether and the ,, ~
'' ~ ether e~tract is dried ovcr anhydrous sodium sulphate. The solution is acid- ,' ,' 20 ified with hydrogen chloride in ether and the semi-solid precipitatei is filter- ' ~ ~ ed off and recrystalIi~ed from ethanol-isopropyl ether. , s!~ ~ Yield: 8.2 g, m.p. 19~-196 . ~ , , ~ Example 15. 4-Dimethylamino-a, a-dimethylphenethylaminedihydro-,..
~ _ chloride (Method D) _ -,~ ~ A solution of 3.5 g of N-~a~a-dimethyl-~-(4-dimethylaminophenyl) . .,.j . .
othyl3acctamide in a nLLYtUre of 25 ml of watcr and 25 ml of conccntratcd hydro~ ,1 chloric acid isrcfllLycd for 16 hours. The solution is thcn evaporatcd under redured prcssure and the rcsiduc is recrystalli-ed twice from mcthanol iso-propyl ethor, Yièld: I.1 g, m.p. 239~5-250~5 , ,ji,. ~ ~ .
~ 20-... . .
~ .
.,:
:~ , f F~ - ~
~ 739~3 :
, In table 1 are gi~rcn data for some end compounds of this invention . ..
includina those described in EYamples 8-15.
In table 2 are gi~en data for some intermediates of this in~ention includin~ those described in EYamp1es 1-7. The products of this table, not e~emplified aboYe, a~e analogously prep~red. The intermediate oily nitro sompounds are used direc~ly ~ithout further purification.
.:
::
, ~ ' ~ ,': ': :
. . .
:, .,' :
: ':
:'~' ' ;: ' ,j , .
'.'~ ~ :,:.
:1: . .
':j~
;
:, .' .
, .:
. . .
-21- ~
:
::~L0'73~13 ~ ~ 0 t~ -1' trl _- _ tO IJ~ O C') ('I ~\ I./7 i~o IJ~ r~
U'0 j t~ t~ . U~ o c, o~ ~ ~ tn ~
~ ~ ~ j o o o l ~ - ~ ~ ~ - ~ ~ ~
t~ ~ It~ ,t~ t~ _~ oo ~ _~ Ico co It~'), . .
tn ~ ~ o ~ er ~ ~ .~ _ rl ~n !
.. U ~ t~ ~ ~ rJ ~ ~O ¦ In t _ ~ 1:
~ ~ O ~t j t~ t~l ~ o _~ o c~ ~ ~r I o _ o t~ `D O ~o t~l ' , ~:~ .. t~ t~ t~ ! O O t~ ~J ~ ~O O O 1~ cO ~D 00I tx~ CO co 5~ t~ ~S - O -- "
:~ , ~ ~~ co I oc 00 oo ~ I oO oo ~ ~ `D ~ t"~ t" u~
.~ .~ q~ ~ ~ ~o ~ t~l lIq ~ t~ ~ Jm ~O t~ ~ '! `' -I ~~ '` o r- o ~D t~ ,, o ~ ~
~ ~ ~ t~~17 tA A ~A ~ tA tn u~ n In oo ~ ~ ~o _ ~ ~ o C~ I Ln In ~t ' I ~1 r~ I h ~I I ~ I ~ I ~1 7-~ I ~t ~ ~ 1 1 ~1 O ;~ ' I h I .
~: _~ t~ ~ C¦ O ~ O ~ tn -- t ~ .~ ~ I ~ O ~ tl~ O C~
:~ _~ ~rl ~ C~ ~ '.-~ t'~ IJ C~ .
, ~ ~ ~ C> j C~C.~ ~ ~ ~ I ~~ C~ O
tl~ O--~ O ~, O--O _~ O -- O ~ O ~ O O ~> O--~ ~ ~ ' O ~
b . ~3 ~ . tJ ~, td P~ ~d ~ ~: ~ td ~ h td ~ ~ ~ ~ &. i td ~ j .': ~ h .C h C u i ~ b ~ O ' ~ O ~ 0 j ~ ~1 ~, O ' v S h b ' ~ f~
~ ~ s~ ~ ~ ¦ 0 ~ 0 P~ ¦ 0 ~ 0 ~ 1 0 ~¦ ~d ~1 0 td Cl ~ ~ i ~ G ~
~ II ~ I I 1 ¦ . , ~ VCC_~ ''-u'l~ ~ ",i t., ~ l I ml Iml ~dol l ~1 IIAI I
} ~ N ~ = ~ ct~ ~ m I `D ~ tn I I ~ ~ ~ ~, D l o~ ¦ ¦ ¦ ¦ ¦ ¦
-~ I f-i i U~, I ~o I I I
t~n~ ~ O . t'~ I o I t~ ~ o Y~ o~ N~ C~ ~ ~
Y ~ `J ~ N ~ ~
~ iY~ U lU lU ~ U 1~
~A l -- ¦
I N I I I I I :~
~ u~ ¦ u l u ¦ u ¦ u ¦ ~ ¦ u ! t~ ¦ u l ~ In l ~~;m I
~ I u~ 8~ lu~ lùo lu~ 18~ lu la~
~lj ~ x ~ 1~
I ~, ~u I= I~ lu I ~ 1 lu ' ~-2 2 - ~ ~
,`: ': : . : ' : : ' :
' . ' ,:` - ' : , ~ ' ':
:;,: - : : :
' . ' ~ f~
Lf073913 :;;
Iu~
VL~ ~ oci ~.
"~ cff ~ u7i f o .~ ~ tcff = M t~
X V ~
V ~--I V
1:~ ~ ~ V h ff ~ffl ~
f VI~ ~ff 3 :5 : ~ :
;-'{'~ ~V `f ¦ ~ r 1~ : N :
r~ 1, ; ~ `
~L0739~L3 R6 .. :
,, I ,.
,,., CH=C-~2 : : .
RZ ~ ~ ~ :
R31~ \ R4~ :
q ~
* R2 ~ ~311 R4 R M.p. C Described in : Example No.
3 ~ H : CH3 ~ CH3 CH3 75-76 1 (b) ; Z~ H ~ C ~ CH3 CH3. Oil tl'~U t.-- U t~U tr~
- V~3 2'5 ~"3 v H~ ~ N ~ 5 ~ C6H5cHz CH3 Oil 3-Cl ~ H : CH3 CH3 ~ CH3 ~93~94 ~ 2 3-Cl ~ ~-CL~ ~C~ ~ ~CH; ~;~ CH3 ~ 113-114 ~ 3 (c) :3-Br : H:~ : CH3 ~ ~ CH3 ~; ~ CH3~ 02-lO3 ~ 5:(b) Pharmacolo~ical tests r~ '.~ It is not possible by:cxperi~ental means to induce depressions in : laboratory animals.~ In ordcr to evaluatc a poss:ible anti-depressive~éffect~On new substances blochemical-pha ~ acological;~test methods~mu~st~be resorted to.~ ~
One~such~mcthod, which seems to ~ive~a good:indication~of~the~pote~tial anti~- :
depressive effccts of tho test substances, ls desoribcd ln~Europ.~J. Pharmacol,~:
17, 107, 197 This method involves thc measurcment of thc potentiation of the syndromes produced by 5-hydroxytryptophan (5-HTP) in a laboratory animal.
The lack of euphoric effects, that is lack of central stimulatory activity, is testcd by measuring the motor activity in mice after administra-tion of the test substance.
Potential anxiolytic activity is tested by measuring the antiag-gressi~ity in isolated mice after administration of the test substance. In *his t~st not amphetamine but Valium ~ - a well-kno~m anxio btic substance -' , is used as a reference.
; 10 5-~TP res~onse potentiation test Inhibition of the uptake of 5-HT potentiates the effects of adminis-tered ~-hydroxytryptophan (5~HTP) probably by increasing the amount of 5-HT at , the receptor. Three mice are gi~en the test drugs one hour (or 4, 24 hours) , before dl-3-HTP, 90 m~k~ i.v~ 5-~TP alone gives only a weak behavioural syn-drome cu* in pretreated mice there is seen a characteristic beha~ioural syn-drome, which somes within fi~e mlnutes: tremor, lordosis~ abduction of the hind1egs~ head-t~itches~
The a~sence or presence of respective syndrome is scored in groups ~
of ten ~ice. The compound was administered in at least five doses and the ~ -,, j , quantal responses were analysed by probit analysis and ED50 determined accord-ing to the method of Litchfield and Wilcoxon.
i ~
Motor activity in mice The explor~tory activitr of mice was recorded in a locomotion cage ~; in ~hich the movements were counted each time the animals cross-ci cuits an . :1 ¦~ elec~rical currcnt in thc bottom plate. Thc acti~ity was recorded for tcn ,':'1 ' ' ` , : , ~11 minutes onc hour after the administration of the d~lg. The animals were ;.1 i tested individuaIly. Groups of six mice were uscd and the micc were only uscd once. The activity was expressed in per ccnt of the acti~ity of control groups ran simultaneously.~ The compounds were administered in at least four doses.
., :
: , . ., . . - .: : : . ,,. ... , . .. , . ... . , . ,: , . . ...... .. . ....
:~10~3g~3 .
The increase ~+) or decrease (-) of the activity comparcd to control n~roups was determined from log dosc response cursres.
Ao~ressive behaviollr in mice ~ lale mice kept isol~ted for 3 weeks or longer develop an aggressive beha~iour s~-hen caged together. The method used follows that of ~'al~elli et al.
~Eur~p ~. Pharmacol. 2, t44, 1967), with -the exception that 2 mice were test-ed on each other. The ag,~ressiveness was scored during a S min test according .
to the followino~ schedule:
O the animals show no interest in each other except occasional nosing ;~ 25 frequent ~igorous nosing and tail rattling, the animals assume a fighting position and occasionally attack each other - no more ~ ~ -~;~ than 3-4 times in the 5 min perlod 5D tail rattling, powerful attacks - no more than 10 times in the test period ~ 75 the animals fo lo~r their partners~ attacking and blting for most 'i of the ti~e '~ ~ lOO;attacks over the entire period.
Controls ar~ministered with the solvent were tested~ the repeated testing~ did no~ influence on the aggressiveness. The animals were used for several e.~periments but ~ith interrals of at least one week.~ Groups of 10 mice were used.
ED50 is the dose which reduces the aggressi~reness score by 50 %.
~j ~ ' '.
~?1~`
S, ,. ~: : ' :, ~ 26- ~
"~
~)73~13 Table , Phar~acological effects of ~-aminoamphetaminc derivatiYes ;~ R _ ~ R
`:: ' 1' 11 R ~ ~ ~ ~
N
~: R3 1 \ R4 Compound~ : ~ Potentiation Motor Anti~
: ? ~6 of 5-HTP Activity aggressive .~: Rl : R R3 R4 R5 R ED ~ = increase behaviour :
, ~ 50 mg/kg _ -~decrease in mice ~::
i.p.0 = no~ effect ED50 mg/kg: ~ -. p .
Valium ~ 2.5 : A3ph-tanine >5 1 : . p-A~dn~amphetaDine ~: 11.5 ~
p-Chl~roa~phetaQine . ¦ 0.8~ 0.3 H ~ H C2~5 C2i~5 H~ CH3 2 ~ : 5-10 2-Cl CH3 CH3 H CH3 0.25 ~ _ : : :2:.5-5 :~
H~ ~ H ~ C2H5 H H CH3 1 1:.25 H~ -2-CH3 CH3 3 H ~ C1l3 0.6 ~ 2.5-5 H: 1~: C2H5:CH3 ~ ~I Clt3 0.7 ~5 ~ H~ 3-B~: CH ~ 1 ~5 ;f ~ ; 2-Cl ~ 6-Cl~ GH3 CH3 ~ CH3 0.1 - ~>5 H :~ ~: H~ ~ C113 -~2)3- ~ a ~1:.5 >5 2-Br C~l3 C~I C1~3 0.1 : i~
H::~ 11 CH3 C1~3C~l3 C~3 :~2.5 H Z-Cl CH3 CH3H C21i5~ 0.25 : ~ Not testcd, ~ue to inter~erence with motor activity ~: .
As can be seen from tho test ~alues o~ Table 3 thei tested:substances:: ;~
5~ diffcr considerably in actiYity from ampheeamine both qualitatively and quant-: itativ~ly. In contrast~to ampheta~ine thc:~tested compo-~ds:of:the invention strongly~potcntlato the 5-HTP response. Furthermore the tested c;ompounds lack ~ . .
the ~central stimulation which is pronounccd after amphotamlne and p-chloro~
- ~ r .
1~3~ ff , .
amphet~mine. The tcsted compounds rather givo a weak sedation. Thus, the potential antidcprcssive activity as indicated by the potentiation of o-H'rP
and the lack of central stimulatory activity may give the compoullds of this invention value as potential antidcpressive agents.
The tested compounds antagonize the aggressive behaviour of male mice which have been kept isolated for one month or more. Many of the com-'~ ~ pounds are at least as active as Valium in this test which may indicate that ,~ these compounds may have therapeutic value as anxiolytic compounds.
~1 " '.' ~' ..
.
~,,f~
f, :~: f ~!r tJ, f~
~' ~ ' ` ' ' `" "''' " ' ' ,', ' ' '~'~ 1 ~: ; ; :. :
! I; - - ' ., ': :
.! ', ~ ~ 28 ., . ~ , . . . , ~ .. , ~ . . : ,. . . . .. . .:
Claims (13)
PROPERTY OR PRIVILEGE IS CLAIMED ARE. DEFINED AS FOLLOWS:
1. A process for the preparation of a compound conforming to the general formula:
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; X represents either (i) a group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, R represents a lower alkyl group or a benzyl group, and R4 represents a lower alkyl group, a benzyl group or a -CH2CH2CH2 bridge con-nected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or (b) X is a group as hereinbefore defined and R is a methyl group, R4 is a methyl group and R5 represents a hydrogen atom, which comprises either:-(a) reacting an aldehyde of the formula III:- III
wherein R1, R2, R4 and R are as defined above with a nitro alkane of the formula :
wherein R6 is as defined above; or (b) reacting a compound of the formula:
or a compound of the formula:
wherein R, R1, R2, R4, R5 and R6 are as defined above, with an alkali metal cyanide or nitrile.
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; X represents either (i) a group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, R represents a lower alkyl group or a benzyl group, and R4 represents a lower alkyl group, a benzyl group or a -CH2CH2CH2 bridge con-nected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or (b) X is a group as hereinbefore defined and R is a methyl group, R4 is a methyl group and R5 represents a hydrogen atom, which comprises either:-(a) reacting an aldehyde of the formula III:- III
wherein R1, R2, R4 and R are as defined above with a nitro alkane of the formula :
wherein R6 is as defined above; or (b) reacting a compound of the formula:
or a compound of the formula:
wherein R, R1, R2, R4, R5 and R6 are as defined above, with an alkali metal cyanide or nitrile.
2. A process according to claim 1(a), in which the reaction is effected by reacting the aldehyde of formula III with excess nitroalkane in the presence of a base.
3. A process according to claim 2 in which the reaction is effected in a solvent.
4. A process according to claim 2 in which the base is ammonium acetate and the reaction is effected in the presence of n-propyl alcohol, ethanol or acetic acid as solvent.
5. A process to claim 1(b) in which the reaction is effected in the presence of a strong acid.
6. A process according to claim 5 in which the strong acid is sulphuric acid.
7. A compound conforming to the general formula:
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; X represents either (i) group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, R represents a lower alkyl: group or a benzyl group, and R4 represents a lower alkyl group, a benzyl group or a -CH2CH2CH2 bridge connected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or (b) X is a group as hereinbefore defined and R is a methyl group, R4 is a methyl group and R5 represents a hydrogen atom, whenever prepared by the process of claim 1 or by an obvious chemical equivalent thereof.
(A) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom; X represents either (i) group or (ii) a group , in which R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group and Z is a lower aliphatic acyl group, R represents a lower alkyl: group or a benzyl group, and R4 represents a lower alkyl group, a benzyl group or a -CH2CH2CH2 bridge connected to the phenyl ring in the ortho-position relative to the N-substituent, with the provisos that R1 and/or R2 represents lower alkyl group or a halogen atom when either (a) X is a and R and R4 both represent a methyl or ethyl group or (b) X is a group as hereinbefore defined and R is a methyl group, R4 is a methyl group and R5 represents a hydrogen atom, whenever prepared by the process of claim 1 or by an obvious chemical equivalent thereof.
8. A compound of the general formula in which formula R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atoms, R3" represents a lower alkyl group or a benzyl group R4 represents a lower alkyl group, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl ring in ortho-position relative to the N-substituent, and R6 represents a lower alkyl group, provided that R1 and/or R2 represents a lower alkyl group or a halogen atom when R3" and R4 both represent a methyl group or an ethyl group whenever prepared by the process of claim 2 or by an obvious chemical equivalent thereof.
9. A compound of the formula or a salt thereof, wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl or a halogen atom, R3 represents a lower alkyl group or a benzyl group, R4 represents a lower alkyl group, a benzyl group or a CH2CH2CH2-bridge connected to the phenyl ring in ortho-position relative to the N-substituent, R5 represents a hydrogen atom or a methyl group, R6 is a lower alkyl group, and Z is a lower alipha-tic acyl group, provided that R1 and/or R2 represents a lower alkyl group or a halogen atom when R3 is a methyl group, R4 is a methyl group, and R5 represents a hydrogen atom, whenever prepared by the process of claim 5 or by an obvious chemical equivalent thereof.
10. A process according to claim 1 in which R and R4 are methyl groups, R1 is a methyl group in the 3-position, R2 is a hydrogen atom and R6 is a methyl group.
11. A process for the preparation of N,N-dimethyl-3-methyl-4-(2-nitropropenyl) aniline which comprises reacting 4-dimethylamino-2-methyl-benzaldehyde with nitroethane.
12. A process according to claim 11 in which the reaction is effected in the presence of ammonium acetate.
13. N,N-dimethyl3-3methyl-4-(2-nitropropenyl) aniline whenever prepared by the process of claim 11 or 12 or by an obvious chemical equivalent thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA318,312A CA1073913A (en) | 1973-09-04 | 1978-12-20 | Amphetamine derivatives |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7312001A SE382047B (en) | 1973-09-04 | 1973-09-04 | PROCEDURE FOR THE PREPARATION OF 4-AMINOAMPHETAMINE DERIVATIVES |
| CA208,356A CA1051436A (en) | 1973-09-04 | 1974-09-03 | 4-amino-amphetamine derivatives |
| CA318,312A CA1073913A (en) | 1973-09-04 | 1978-12-20 | Amphetamine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1073913A true CA1073913A (en) | 1980-03-18 |
Family
ID=27163602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA318,312A Expired CA1073913A (en) | 1973-09-04 | 1978-12-20 | Amphetamine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1073913A (en) |
-
1978
- 1978-12-20 CA CA318,312A patent/CA1073913A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1087205A (en) | 2-amino-3-(5-and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
| SU820659A3 (en) | Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers (their variations) | |
| DK155327B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 5H-2,3-BENZODIAZEPINE DERIVATIVES OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT | |
| CA1043349A (en) | Therapeutic 1-hydroxyaryl-2-amidoalkylaminoethanol derivatives | |
| JPH0272136A (en) | Naphthalene derivative, production and synthetic intermediate thereof | |
| US3936461A (en) | Substituted 4-benzylquinolines | |
| US3326930A (en) | alpha-halomethyl-(1-oxazole-carbonylindol-3-yl) acetic acids and certain intermediates therefor | |
| US4503073A (en) | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids | |
| CA1189859A (en) | 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them | |
| JPS604187B2 (en) | Method for producing 4-aminoquinoline derivative | |
| JPS6019757B2 (en) | Novel thieno-[2,3-c]- and -[3,2-c]-pyridine derivatives, methods for producing the same, and therapeutic compositions containing the same | |
| CA1051436A (en) | 4-amino-amphetamine derivatives | |
| US4000280A (en) | Pharmaceutical compositions containing an amphetamine derivative for the alleviation of anxiety or treatment of depression | |
| Buchman et al. | Antihypertensive 5, 6-diarylpyridazin-3-ones | |
| EP0083222B1 (en) | New quinolylacetic acid compounds and pharmaceutical compositions containing them | |
| US3647802A (en) | 2-amino-4-aryl-3 4-dihydroquinolines | |
| CA1078395A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
| AU609068B2 (en) | Compounds useful as intermediates for the production of substituted 1-pyridlyoxy-3-indolyalkylamino-2-propanols | |
| US4232160A (en) | Isoquinoline propionamides exhibiting analgesic properties | |
| JPS6191172A (en) | 2-Pyridine-thiol derivative, method for producing the same, and pharmaceutical composition containing the same | |
| JPH0710863B2 (en) | Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament | |
| Speziale et al. | Pyranylation of Amides | |
| US3849438A (en) | 2-substituted-3-disubstituted-4,5,6,7-substituted or unsubstituted phthalimidines | |
| US4452982A (en) | Process for the preparation of nitrogen-bridgehead condensed pyrimidine compounds, and pharmaceutical compositions containing them | |
| CA1055949A (en) | 4-aryl-1,2,3,4-tetrahydropyrrolo(3,4-b) indoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |